CCR8 antigen binding units and uses thereof
By developing antigen-binding units that specifically bind CCR8, blocking their binding to CCL1 and enhancing ADCC activity, the problem of Treg cell inhibition in existing immunotherapy is solved, and the tumor's sensitivity to immunotherapy and therapeutic effect is improved.
Patent Information
- Application Number
- CN202280080188.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-02
- Filing Date
- 2022-12-02
- Publication Date
- 2024-12-03
Smart Images

Figure BDA0004872666580000181 
Figure BDA0004872666580000191 
Figure BDA0004872666580000201
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of antibody-based therapeutics. More specifically, the present disclosure relates to anti-CCR8 compositions and methods of using them to treat disease. Background Art
[0002] Despite the promise of immunotherapy for cancer treatment, nearly 80% of patients do not respond to checkpoint inhibitor (CPI) therapy. Regulatory T cells (Tregs) suppress immune responses in the tumor microenvironment through multiple inhibitory mechanisms and have been implicated as playing a key role in the lack of CPI efficacy. Therefore, targeted elimination of Tregs may promote more effective anti-tumor immunity. CCR8 is a chemokine receptor that is selectively expressed on activated human intratumoral Tregs, and these intratumoral CCR8+ Tregs have been shown to drive immunosuppression, leading to poor prognosis. Therefore, CCR8 can be targeted for cancer immunotherapy by selectively depleting intratumoral immunosuppressive Treg cells. Antibodies targeting human CCR8 can lead to Treg depletion in tumors and sensitize tumors to CPI treatments such as anti-PD-1 therapy. SUMMARY OF THE INVENTION
[0004] Disclosed herein are antigen binding units comprising a light chain complementary determining region (CDR) (referring to a light chain variable region) and a heavy chain CDR (referring to a heavy chain variable region). In some aspects, the antigen binding unit binds to CCR8 and prevents CCR8 from binding to CC motif chemokine ligand 1 (CCL1) expressed on the surface of immune cells.
[0005] In some embodiments, when the antigen binding unit is linked to a crystallizable fragment (Fc) region, particularly a mutant Fc variant, it exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC), thereby killing Treg cells expressing CCR8.
[0006] In some embodiments, the antigen binding unit comprises at least one mutation at a post-translational modification (PTM) site. In some embodiments, the at least one mutation is at least one of the following: N28G mutation, N28Q mutation, N28I mutation, N28S mutation, G29A mutation, G29I mutation and G29V mutation. In some embodiments, the mutation is the N28G mutation in the light chain CDR1.
[0007] In some embodiments, the heavy chain CDR comprises a HC-CDR1, a HC-CDR2, and a HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 each comprise a sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 13-15, 19-22, 71-73, 77, 78, 81, 83-85, 89, 91-93, 97, 98, and 112-118, including any ranges having these values as endpoints (e.g., 60%-85%).
[0008] In some embodiments, the heavy chain CDR comprises HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 13-15, 19-22, 71-73, 77, 78, 81, 83-85, 89, 91-93, 97, 98, and 112-118.
[0009] In some embodiments, the heavy chain CDR comprises HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 each comprise a sequence selected from the group consisting of: SEQ ID NOs: 13-15, 19-22, 89, 114, and 115.
[0010] In some embodiments, the heavy chain CDR comprises HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 each comprise a sequence selected from the group consisting of: SEQ ID NOs: 83-85 and 116-118.
[0011] In some embodiments, HC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 13, 71, 83, 115, and 117, HC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 14, 72, 77, 84, 89, 91, 92, 97, 114, 116, and 118, and HC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 15, 19-22, 73, 78, 81, 85, 93, 98, 112, and 113.
[0012] In some embodiments, HC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 13 and 115, HC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 14, 89, and 114, and HC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 15 and 19-22.
[0013] In some embodiments, HC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 83 and 117, HC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 84, 116, and 118, and HC-CDR3 comprises the sequence of SEQ ID NO: 85.
[0014] In some embodiments, the light chain CDR comprises LC-CDR1, LC-CDR2 and LC-CDR3, wherein the LC-CDR1, LC-CDR2 and LC-CDR3 each comprise a sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a sequence selected from SEQ ID NOs: 16-18, 23, 24, 25, 74-76, 79, 80, 82, 86-88, 90, 94-96 and 99-111, including any ranges with these values as endpoints (e.g., 60%-85%).
[0015] In some embodiments, the light chain CDR comprises LC-CDR1, LC-CDR2 and LC-CDR3, wherein the LC-CDR1, LC-CDR2 and LC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NO: 16-18, 23, 24, 25, 74-76, 79, 80, 82, 86-88, 90, 94-96 and 99-111.
[0016] In some embodiments, the light chain CDR comprises LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, LC-CDR2, and LC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 16-18, 23, 24, 25, 90, and 102-106.
[0017] In some embodiments, the light chain CDR comprises LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, LC-CDR2, and LC-CDR2 each comprise a sequence selected from the group consisting of: SEQ ID NOs: 86-88.
[0018] In some embodiments, the LC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 16, 74, 79, 86, 90, 94, 99, and 102-109, the LC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 17, 75, 80, 87, 95, 100, 110, and 111, and the LC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 18, 23-25, 76, 82, 88, 96, and 101.
[0019] In some embodiments, LC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 16, 90, and 102-106, LC-CDR2 comprises a sequence of SEQ ID NO: 17, and LC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 18 and 23-25.
[0020] In some embodiments, the LC-CDR1 comprises the sequence of SEQ ID NO:86, the LC-CDR2 comprises the sequence of SEQ ID NO:87, and the LC-CDR3 comprises the sequence of SEQ ID NO:88.
[0021] In some embodiments, the heavy chain CDR comprises HC-CDR1, HC-CDR2 and HC-CDR3, wherein the HC-CDR1, HC-CDR2 and HC-CDR3 respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 19; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 20; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 21; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 22; SEQ ID NO: 71, SEQ ID NO: 72 and SEQ ID NO: 73; SEQ ID NO: 71, SEQ ID NO: 77 and SEQ ID NO: 78; SEQ ID NO: 71, SEQ ID NO: 72 and SEQ ID NO: 81; SEQ ID NO: 83, SEQ ID NO: 84 and SEQ ID NO: 85; SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88; SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95; SEQ ID NO: SEQ ID NO:13, SEQ ID NO:89 and SEQ ID NO:15; SEQ ID NO:13, SEQ ID NO:91 and SEQ ID NO:15; SEQ ID NO:71, SEQ ID NO:92 and SEQ ID NO:93; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:98; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:112; SEQ ID NO:13, SEQ ID NO:97, and SEQ ID NO:113; SEQ ID NO:13, SEQ ID NO:114, and SEQ ID NO:15; SEQ ID NO:115, SEQ ID NO:114, and SEQ ID NO:15; SEQ ID NO:83, SEQ ID NO:116, and SEQ ID NO:85; SEQ ID NO:117, SEQ ID NO:116 and SEQ ID NO:85; and SEQ ID NO:83, SEQ ID NO:118 and SEQ ID NO:85.
[0022] In some embodiments, the light chain CDR comprises LC-CDR1, LC-CDR2 and LC-CDR3, wherein the LC-CDR1, LC-CDR2 and LC-CDR3 respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 23; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 24; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 25; SEQ ID NO: 74, SEQ ID NO: 75 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 75 and SEQ ID NO: 82; SEQ ID NO: 86, SEQ ID NO: 87 and SEQ ID NO: 88; SEQ ID NO: 90, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 1 SEQ ID NO:94, SEQ ID NO:95 and SEQ ID NO:96; SEQ ID NO:79, SEQ ID NO:75 and SEQ ID NO:76; SEQ ID NO:99, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:101, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:103, SEQ ID NO:17 and SEQ ID SEQ ID NO:104, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:105, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:106, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:107, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:108, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:109, SEQ ID NO:100 and SEQ ID NO:101; and SEQ ID NO:99, SEQ ID NO:111 and SEQ ID NO:101.
[0023] In some embodiments, the heavy chain CDR comprises HC-CDR1, HC-CDR2, and HC-CDR3, and the light chain CDR comprises LC-CDR1, LC-CDR2, and LC-CDR3, wherein the HC-CDR1, HC-CDR2, HC-CDR3, LC-CDR1, LC-CDR2, and LC-CDR3 respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, 16, 17, and 18; SEQ ID NOs: 13, 14, 19, 16, 17, and 18; SEQ ID NOs: 13, 14, 20, 16, 17, and 18; SEQ ID NOs: 13, 14, 21, 16, 17, and 18; SEQ ID NOs: 13, 14, 22, 16, 17, and 18; SEQ ID NOs: 13, 14, 15, 16, 17, and 23; SEQ ID NOs: 13, 14, 15, 16, 17, and 23; NO:13, 14, 15, 16, 17 and 24; SEQ ID NO:13, 14, 15, 16, 17 and 25; SEQ ID NO:13, 14, 19, 16, 17 and 23; SEQ ID NO:13, 14, 20, 16, 17 and 23; SEQ ID NO:13, 14, 21, 16, 17 and 23; SEQ ID NO:13, 14, 22, 16, 17 and 23; SEQ ID NO:13, 89, 15, 90, 17 and 18; SEQ ID NO:13, 89, 15, 102, 17 and 18; SEQ ID NO:13, 89, 15, 103, 17 and 18; SEQ ID NO:13, 89, 15, 104, 17 and 18; SEQ ID NO:13, 89, 15, 16, 17 and 18; NO: 13, 89, 15, 105, 17 and 18; SEQ ID NO: 13, 89, 15, 106, 17 and 18; SEQ ID NO: 13, 114, 15, 16, 17 and 18; and SEQ ID NO: 115, 114, 15, 16, 17 and 18.
[0024] In some embodiments, the heavy chain CDR comprises HC-CDR1, HC-CDR2 and HC-CDR3, and the light chain CDR comprises LC-CDR1, LC-CDR2 and LC-CDR3, wherein the HC-CDR1, HC-CDR2, HC-CDR3, LC-CDR1, LC-CDR2 and LC-CDR3 respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87 and 88; SEQ ID NOs: 83, 116, 85, 86, 87 and 88; SEQ ID NOs: 117, 116, 85, 86, 87 and 88; and SEQ ID NOs: 83, 118, 85, 86, 87 and 88.
[0025] In some embodiments, the antigen binding unit comprises a heavy chain CDR comprising a sequence that is at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NO: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70, including any ranges with these values as endpoints (e.g., 60%-85%).
[0026] In some embodiments, the antigen binding unit comprises a heavy chain CDR comprising a sequence selected from the group consisting of SEQ ID NO: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70.
[0027] In some embodiments, the antigen binding unit includes a light chain CDR comprising a sequence that is at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence selected from SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60 and 62-65, including any ranges with these values as endpoints (e.g., 60%-85%).
[0028] In some embodiments, the antigen binding unit comprises a light chain CDR comprising a sequence selected from the group consisting of SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60, and 62-65.
[0029] In some embodiments, the antigen binding unit comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR and the light chain CDR respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 2; SEQ ID NOs: 3 and 2; SEQ ID NOs: 4 and 2; SEQ ID NOs: 5 and 2; SEQ ID NOs: 6 and 2; SEQ ID NOs: 7 and 2; SEQ ID NOs: 1 and 8; SEQ ID NOs: 1 and 9; SEQ ID NOs: 1 and 10; SEQ ID NOs: 3 and 8; SEQ ID NOs: 4 and 8; SEQ ID NOs: 5 and 8; SEQ ID NOs: 6 and 8; SEQ ID NOs: 11 and 8; SEQ ID NOs: 12 and 8; SEQ ID NOs: 34 and 35; SEQ ID NOs: 34 and 43; SEQ ID NOs: 34 and 44; SEQ ID NOs: 34 and 45; SEQ ID NOs: 34 and 46; SEQ ID NOs: 34 and 47; SEQ ID NOs: 34 and 48; SEQ ID NOs: 56 and 2; SEQ ID NOs: 57 and 58; SEQ ID NOs: 59 and 60; SEQ ID NOs: 61 and 62; SEQ ID NOs: 63 and 64; SEQ ID NOs: 65 and 66; SEQ ID NOs: 67 and 68; SEQ ID NOs: 69 and 70; SEQ ID NOs: 71 and 72; SEQ ID NOs: 73 and 74; SEQ ID NOs: 75 and 76 NO:57 and 2; SEQ ID NO:58 and 2; SEQ ID NO:59 and 2; SEQ ID NO:56 and 60; SEQ ID NO:57 and 60; SEQ ID NO:58 and 60; and SEQ ID NO:58 and 60. In some embodiments, the heavy chain CDR and the light chain CDR respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NO:1 and 2; SEQ ID NO:3 and 2; SEQ ID NO:4 and 2; SEQ ID NO:5 and 2; SEQ ID NO:6 and 2; SEQ ID NO:7 and 2; SEQ ID NO:1 and 8; and SEQ ID NO:1 and 9.
[0030] In some embodiments, the antigen binding unit comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR and the light chain CDR respectively comprise an amino acid sequence selected from the following groups: SEQ ID NOs: 32 and 33; SEQ ID NOs: 61 and 62; SEQ ID NOs: 61 and 63; SEQ ID NOs: 61 and 64; SEQ ID NOs: 61 and 65; SEQ ID NOs: 66 and 62; SEQ ID NOs: 67 and 62; SEQ ID NOs: 68 and 62; SEQ ID NOs: 69 and 62; and SEQ ID NOs: 70 and 62.
[0031] In some embodiments, the antigen binding unit comprises an IgG1 framework, with or without mutations in the Fc region.
[0032] In some embodiments, the antigen binding unit is a monoclonal antibody, a humanized antibody or a chimeric antibody. In some embodiments, the antigen binding unit is a scFv, Fab', single-chain Fab (scFab'), Fd or F(ab')2, sFC, Fv or ccFv. In some embodiments, the antigen binding unit competes for the binding of the epitope recognized by the antigen binding unit.
[0033] In other embodiments, a pharmaceutical composition comprising any of the antigen binding units disclosed herein and a pharmaceutically acceptable excipient is provided.
[0034] In other embodiments, isolated nucleic acids encoding any of the antigen binding units disclosed herein are provided.
[0035] In other embodiments, a vector comprising a nucleic acid sequence encoding any of the antigen binding units disclosed herein is provided.
[0036] In other embodiments, a host cell expressing any of the antigen binding units disclosed herein is provided.
[0037] In other embodiments, a host cell comprising a nucleic acid encoding any of the antigen binding units disclosed herein is provided.
[0038] In other embodiments, a method for preparing any of the antigen binding units disclosed herein is provided. The method comprises culturing any host cell disclosed herein under conditions suitable for expressing the antigen binding unit; and isolating the antigen binding unit expressed by the host cell.
[0039] In other embodiments, a method for eliminating an immune cell population is provided. The method includes contacting an immune cell with any antigen binding unit disclosed herein. In some aspects, the immune cell is a regulatory T cell (Treg). In other embodiments, the immune cell is a Treg resident in a tumor.
[0040] In other embodiments, a method for treating a cancer in a subject in need is provided. The method comprises administering an effective amount of an antigen binding unit as described herein to a subject in need. In embodiments, the method comprises repeating the administration step for a period of time, such as until the subject has no cancer. In some embodiments, the cancer is a blood cancer or a solid tumor. In some embodiments, treating cancer comprises reducing tumor volume.
[0041] In other embodiments, a method for treating cancer in a subject in need is provided. The method comprises administering to a subject in need an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and any antigen binding unit disclosed herein. In some embodiments, the method comprises repeating the administration step for a period of time, such as until the subject is free of cancer. In some embodiments, the cancer is a blood cancer or a solid tumor. In some embodiments, treating cancer comprises reducing tumor volume. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 A multiple sequence alignment of the amino acid sequences of human, cynomolgus monkey, mouse and rat CCR8 is shown.
[0043] Figure 2A-2C Antibodies with post-translational modification (PTM) sites removed were shown to bind to HEK293 human CCR8, HEK293 cells, and HEK293-cynomolgus monkey CCR8.
[0044] Figure 3A-3B It was shown that antibodies with post-translational modification (PTM) sites removed blocked the binding of human CCL1 to CHO-K1-human CCR8 cells.
[0045] Figure 4A-4B Binding of the indicated humanized antibodies to ExpiCHO-S-CCR1 and ExpiCHO-S-CCR4 cells is shown.
[0046] Figure 5A-5B The antibody-dependent cellular cytotoxicity (ADCC) activity of the humanized antibody against the CHO-K1-human CCR8 cell line was shown.
[0047] Figure 6 Anti-CCR8 was shown to inhibit CCL1-induced recruitment of β-arrestin.
[0048] Figure 7 The ability of humanized anti-CCR8 antibodies to block CCL1-induced cell migration is shown.
[0049] Figures 8A-8B FACS binding of periplasmic extract (PPE) to CHO-K1-human CCR8 cells is shown.
[0050] Figures 9A-9B The ability of affinity matured antibodies to inhibit CCL1-induced β-arrestin recruitment is shown.
[0051] Fig.10 Mature anti-CCR8 antibodies were shown to block CCL1-induced cell migration.
[0052] Figures 11A-11B Binding of the Fc variants of humanized 149 and humanized 348 antibodies to HuT78 cells is shown.
[0053] Figures 12A-12B The ADCC activity of V variant CD16a / NFAT-Jurkat cells against CHO-K1-human CCR8 cells is shown.
[0054] Figures 13A-13B The ADCC activity of F variant CD16a / NFAT-Jurkat cells against CHO-K1-human CCR8 cells is shown.
[0055] Figures 14A-14B The ADCC activity of V variant CD16a / NFAT-Jurkat cells against HuT78 cells is shown.
[0056] Figures 15A-15B The ADCC activity of F variant CD16a / NFAT-Jurkat cells against HuT78 cells is shown.
[0057] Figures 16A-16B The ADCC activity of human PBMC cells against CHO-K1-human CCR8 cells is shown.
[0058] Figures 17A-17B The ability of affinity matured antibodies to inhibit CCL1-induced β-arrestin recruitment is shown.
[0059] Fig.18 The main immune cell populations in peripheral blood were shown to not express CCR8. PBMCs from a renal cell carcinoma patient (patient number 200003119) were analyzed by flow cytometry.
[0060] Fig.19 CCR8 was shown to be expressed exclusively by Tregs from hDTCs. Renal hDTCs from patient number 200003119 were analyzed by flow cytometry.
[0061] Fig. 20 A-20N shows that CCR8 is expressed by Tregs from hDTCs in different cancer types. Two CCR8 subsets were observed (Subset 1: CCR8 low (lo) and Subset 2: CCR8 high (hi)).
[0062] Fig.21 Treatment with Hu149-11G1m showed a significant reduction in tumor volume.
[0063] Fig. 22 Shown is a graph of tumor volume versus days after tumor implantation in different treatment groups (Control, Hu149-11G1m, Anti-PD-1, and Combo) in a study using hCCR8 knock-in transgenic mice inoculated with M38 tumors.
[0064] Fig.23 Kaplan-Meier survival plot showing the percentage (%) of animal survival in different treatment groups (Control, Hu149-11G1m, Anti-PD-1 and Combo) versus days after tumor implantation in a study using hCCR8 knock-in transgenic mice inoculated with M38 tumors.
[0065] Fig.24 Shown is a graph of tumor volume versus days after tumor implantation in different treatment groups (Control, Hu149-11G1m, Anti-PD-1, and Combo) in a study using hCCR8 knock-in transgenic mice inoculated with E0771 tumors.
[0066] Fig.25 Kaplan-Meier survival plot showing the percentage (%) of animal survival in different treatment groups (Control, Hu149-11G1m, Anti-PD-1 and Combo) versus days after tumor implantation in a study using hCCR8 knock-in transgenic mice inoculated with E0771 tumors.
[0067] Fig.26 Shown is flow cytometric analysis of immune cell populations in E0771 tumors at day 7 after initiation of treatment. DETAILED DESCRIPTION OF THE INVENTION
[0069] Although preferred embodiments of the present disclosure have been shown and described herein, it is obvious to those skilled in the art that these embodiments are provided only by way of example. Without departing from the present application, many changes, modifications and replacements will now occur to those skilled in the art. It should be understood that various alternatives of the present application embodiments described herein can be adopted when practicing the present application. It is contemplated that the following claims define the scope of the application, and methods and structures within the scope of these claims and their equivalents are thus covered.
[0070] I. Definitions
[0071] For convenience, certain terms used in the specification, examples, and claims are collected here. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0072] If a range of values is provided, it is understood that it includes every intervening value between the upper and lower limits of the range and any other specified value or intervening value in the range that is between one-tenth of the unit of the lower limit unless the context clearly dictates otherwise. The upper and lower limits of these smaller ranges may independently be included in these smaller ranges and are also included in the stated range, subject to any specifically excluded limits in the stated range. If the stated range includes one or both limits, ranges excluding either or both are also included.
[0073] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0074] When immediately preceding a numerical value, the word "about" means a range of plus or minus 10% of the value, e.g., "about 50" means 45-55, "about 25,000" means 22,500-27,500, etc., unless the context of the present disclosure indicates otherwise or is inconsistent with such an interpretation. For example, in a numerical list such as "about 49, about 50, about 55," "about 50" means a range extending to less than half of the interval between the preceding and succeeding values, e.g., greater than 49.5 to less than 52.5. In addition, the phrases "less than about" a value or "greater than about" a value should be understood according to the definition of the term "about" provided herein.
[0075] The compositions of the present disclosure may comprise, consist essentially of, or consist of the disclosed components.
[0076] All percentages, parts and ratios are based upon the total weight of the topical composition and all measurements made are at about 25°C, unless otherwise specified.
[0077] The phrase "pharmaceutically acceptable" as used herein refers to those compounds, salts, compositions, dosage forms, etc., which are suitable for use in contact with the tissues of humans and / or other mammals without excessive toxicity, irritation, allergic response, or other problems or complications within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio. In some aspects, "pharmaceutically acceptable" means approved by a U.S. federal or state government regulatory agency, or listed in the United States Pharmacopeia or other generally recognized pharmacopeia, for use in mammals (e.g., animals), especially humans.
[0078] For example, as used herein, the term "treatment" refers to a method of treating cancer, and generally includes administering a compound or composition that reduces the frequency of symptoms of a subject's medical condition (e.g., cancer) or delays the onset of symptoms compared to a subject who has not received the compound or composition. This can include reversing, reducing, or preventing symptoms, clinical signs, and underlying pathology in a manner that improves or stabilizes the subject's condition (e.g., regression of tumor growth).
[0079] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein and refer to polymers of amino acids of any length. The polymer may be linear, cyclic or branched, may contain modified amino acids, and may be interrupted by non-amino acids. These terms also encompass amino acid polymers that have been modified, for example, by sulfation, glycosylation, lipidation, acetylation, phosphorylation, iodination, methylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenization, transfer RNA-mediated addition of amino acids to proteins, such as arginylation, ubiquitination or any other manipulation, such as conjugation with a labeling component. As used herein, the term "amino acid" refers to natural and / or non-natural or synthetic amino acids, including glycine and D or L optical isomers, as well as amino acid analogs and peptide mimetics. "Derived from" a polypeptide or amino acid sequence of a specified protein refers to the source of the polypeptide. Preferably, the polypeptide has an amino acid sequence substantially identical to the amino acid sequence of the polypeptide encoded in the sequence, or a portion thereof, wherein the portion consists of at least 10-20 amino acids, or at least 20-30 amino acids, or at least 30-50 amino acids, or the amino acid sequence is immunologically recognizable with the polypeptide encoded in the sequence. The term also includes polypeptides expressed from a specified nucleic acid sequence.
[0080] As used herein, the term "antigen binding unit" refers to immunoglobulin molecules and immunologically active portions of immunoglobulins, i.e., molecules containing antigen binding sites that specifically bind ("immunoreact with...") antigens. The term "antigen binding unit" also includes immunoglobulin molecules from a variety of species, including invertebrates and vertebrates. Structurally, the simplest naturally occurring antibodies (e.g., IgG) include four polypeptide chains, two heavy (H) chains, and two light (L) chains, which are interconnected by disulfide bonds. Immunoglobulins are a large class of molecules, including various types of molecules, such as IgD, IgG, IgA, IgM, and IgE. The term "immunoglobulin molecule" includes, for example, hybrid antibodies or altered antibodies and fragments thereof. It has been shown that the antigen binding function of an antibody can be achieved by fragments of naturally occurring antibodies. These fragments are collectively referred to as "antigen binding units". The term "antigen binding unit" also includes any molecular structure containing polypeptide chains, which has a specific shape that matches and recognizes an epitope, wherein one or more non-covalent binding interactions can stabilize the complex between the molecular structure and the epitope.
[0081] An antigen binding unit "specifically binds" or "immunoreacts" with an antigen if it binds to that antigen with greater affinity or avidity than it binds to one or more other reference antigens (including polypeptides or other substances).
[0082] As used herein, "antigen" refers to a substance that is specifically recognized and bound by an antigen binding unit. Antigens may include peptides, proteins, glycoproteins, polysaccharides, and lipids; portions thereof, and combinations thereof. Non-limiting exemplary antigens include CCR8 from humans, mice, and other homologs thereof.
[0083] The term "biological sample" covers various sample types obtained from an organism and used for diagnostic or monitoring analysis. The term covers blood and other fluid samples, solid tissue samples of biological origin, such as biopsy samples or tissue cultures, or cells derived therefrom and their progeny. The term covers samples that have been manipulated in any way after procurement, such as treatment with reagents, solubilization, or enrichment for certain components. The term covers clinical samples and also includes cells in cell culture, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples.
[0084] A "chimeric" protein comprises at least one fusion polypeptide that contains regions that are in a different position in the sequence than occurs in nature. These regions may normally exist in separate proteins and are brought together in the fusion polypeptide; or they may normally exist in the same protein but are placed in the fusion polypeptide in a new arrangement. Chimeric proteins can be produced, for example, by chemical synthesis or by creating and translating a polynucleotide in which the peptide regions are encoded in a desired relationship.
[0085] A genetic "database" refers to a set of stored data representing a collection of sequences, including nucleotide and peptide sequences, which in turn represent a collection of biological reference material.
[0086] "Domain" refers to a portion of a protein that is physically or functionally distinct from the rest of a protein or peptide. Physically defined domains include those amino acid sequences that are particularly hydrophobic or hydrophilic, such as those membrane-associated or cytoplasmic-associated. Domains can also be defined by internal homology, for example, resulting from gene duplication. Functionally defined domains have distinct biological functions. For example, the ligand binding domain of a receptor is the domain that binds to a ligand. An antigen binding domain refers to a portion of an antigen binding unit or antibody that binds to an antigen. A functionally defined domain need not be encoded by a continuous amino acid sequence. A functionally defined domain may comprise one or more physically defined domains. For example, a receptor is typically divided into an extracellular ligand binding domain, a transmembrane domain, and an intracellular effector domain.
[0087] As used herein, "expression" refers to the process by which a polynucleotide is transcribed into mRNA and / or the process by which the transcribed mRNA (also referred to as a "transcript") is subsequently translated into a peptide, polypeptide, or protein. Transcripts and encoded polypeptides are collectively referred to as gene products. If the polynucleotide is derived from genomic DNA, expression may include splicing of mRNA in eukaryotic cells.
[0088] "Cell line" or "cell culture" refers to bacterial, plant, insect, or higher eukaryotic cells grown or maintained in vitro. The progeny of a cell may not be completely identical (morphologically, genotypically, or phenotypically) to the parent cell.
[0089] A "fusion gene" is a gene composed of at least two heterologous polynucleotides linked together.
[0090] The terms "gene" or "gene fragment" are used interchangeably herein. They refer to a polynucleotide containing at least one open reading frame that is capable of encoding a specific protein after transcription and translation. A gene or gene fragment may be genomic, cDNA or synthetic, as long as the polynucleotide contains at least one open reading frame, which may cover the entire coding region or a fragment thereof.
[0091] "Heterologous" refers to an entity that is derived from a different genotype than the other entity being compared. For example, a promoter that is removed from its native coding sequence and operably linked to a coding sequence other than the native sequence is a heterologous promoter. The term "heterologous" when applied to a polynucleotide or polypeptide means that the polynucleotide or polypeptide is derived from an entity that is different genotype than the other entity being compared. For example, a heterologous polynucleotide or antigen can be derived from a different species origin, a different cell type, and the same type of cells from different individuals.
[0092] "Host cell" includes individual cells or cell cultures, which can be or have been the recipient of the subject vector.Host cells include the offspring of a single host cell. Due to natural, accidental or deliberate mutations, the offspring may not necessarily be exactly the same as the original parent cell (in terms of morphology or genome or total DNA complement).Host cells include cells transfected in vivo with a vector. "Host cell" can refer to a prokaryotic cell, a eukaryotic cell, or a cell line cultured as a unicellular entity, which can or has been used as a receptor for a recombinant vector or other transfer polynucleotides, and includes the offspring of the original cell that has been transfected.It should be understood that due to natural, accidental or deliberate mutations, the offspring of a single cell may not necessarily be exactly the same as the original parent in terms of morphology or genome or total DNA complement.
[0093] As used herein, the term "isolated" refers to separation from cells and other components, wherein the polynucleotide, peptide, polypeptide, protein, antibody or its fragment is normally associated with it in nature. As known to those skilled in the art, non-naturally occurring polynucleotides, peptides, polypeptides, proteins, antibodies or their fragments do not need to be "isolated" to distinguish them from their naturally occurring counterparts. In addition, the difference between "concentrated", "isolated" or "diluted" polynucleotides, peptides, polypeptides, proteins, antibodies or their fragments and their naturally occurring counterparts is that the concentration or number of molecules per volume is greater than "concentrated" or less than "isolated" compared to their naturally occurring counterparts. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured relative to a second potential interfering substance present in the source mixture. In some embodiments, it is preferred to increase enrichment. Thus, for example, a 2-fold enrichment is preferred, a 10-fold enrichment is more preferred, a 100-fold enrichment is more preferred, and even a 1000-fold enrichment is more preferred. The substance can also be provided in a separated state by an artificial assembly process (such as by chemical synthesis or recombinant expression).
[0094] "Connected" and "fused" or "fusion" are used interchangeably herein. These terms refer to the joining of two or more chemical elements or components by any means, including chemical conjugation or recombinant means. "In-frame fusion" refers to the joining of two or more open reading frames (ORFs) to form a continuous longer ORF in a manner that maintains the correct reading frame of the original ORFs. Therefore, the resulting recombinant fusion protein is a single protein containing two or more fragments that correspond to the polypeptides encoded by the original ORFs (these fragments are not normally connected in this way in nature). Although the reading frame is therefore continuous throughout the fused fragment, the fragments can be physically or spatially separated by, for example, in-frame linker sequences (e.g., "Flexons").
[0095] "Operably linked" or "operably connected" refers to a juxtaposition in which the components are in a relationship that allows them to function in the intended manner. For example, a promoter sequence is operably linked to a coding sequence if the promoter sequence promotes transcription of the coding sequence. For example, a peptide sequence (e.g., Fc) is linked to another peptide sequence (e.g., an antigen binding unit) in a manner that enables a functional structure (e.g., an antibody).
[0096] The terms "polynucleotide", "nucleic acid", "nucleotide" and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or their analogs. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of genes or gene fragments, gene sites (locus) defined by linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, primers, oligonucleotides or synthetic DNA. Polynucleotides can include modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, the nucleotide structure can be modified before or after polymer assembly. The nucleotide sequence may be interrupted by non-nucleotide components. After polymerization, the polynucleotide can be further modified, such as by conjugation with a labeling component.
[0097] "Recombinant" as applied to polynucleotides refers to polynucleotides that are the product of various combinations of cloning, restriction and / or ligation steps and other procedures that produce a construct that is different from the polynucleotide found in nature.
[0098] In the context of polypeptides, a "sequence" is the order of amino acids in a polypeptide in the direction from the amino terminus to the carboxyl terminus, wherein residues adjacent to each other in the sequence are contiguous in the primary structure of the polypeptide. A sequence may also be a linear sequence of a portion of a polypeptide known to contain additional residues in one or both directions.
[0099] "Vector" is a nucleic acid molecule, preferably self-replicating, which transfers the inserted nucleic acid molecule into a host cell and / or between host cells. The term includes vectors primarily used to insert DNA or RNA into cells, vectors primarily used to replicate DNA or RNA, and expression vectors used for DNA or RNA transcription and / or translation. Also included are vectors that provide more than one of the above functions. "Expression vector" is a polynucleotide that, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide. "Expression system" generally refers to a suitable host cell consisting of an expression vector capable of producing the desired expression product.
[0100] As used herein, the terms "treatment / treating / treat" and the like generally refer to obtaining a desired pharmacological and / or physiological effect. The effect may be a preventive effect that completely or partially prevents a disease or its symptoms, and / or may be a therapeutic effect that completely or partially stabilizes or cures a disease and / or adverse effects caused by the disease. As used herein, "treatment" includes any treatment of a disease in a mammal (e.g., mouse, rat, rabbit, pig, primate, including humans and other apes, particularly humans), and includes: (a) preventing a disease or symptom from occurring in a subject who may be susceptible to the disease or symptom but has not yet been diagnosed with the disease or symptom; (b) inhibiting disease symptoms; (c) preventing the development of a disease; (d) alleviating disease symptoms; (e) causing regression of a disease or symptom; or any combination thereof.
[0101] The terms "recipient," "individual," "subject," "host," and "patient" are used interchangeably herein and refer to any mammalian subject, particularly a human, in need of diagnosis, treatment, or therapy.
[0102] The terms "cancer", "tumor", "tumor" and "carcinoma" are used interchangeably herein and refer to cells that exhibit relatively autonomous growth, so that they exhibit an abnormal growth phenotype characterized by a significant loss of control of cell proliferation. Typically, the target cells detected or treated in the present application include precancerous (e.g., benign), malignant, pre-metastatic, metastatic and non-metastatic cells. The term "normal", used in the context of "normal cells", refers to cells of an untransformed phenotype or cells that exhibit the morphology of untransformed cells of the tissue type being examined. "Cancer phenotype" generally refers to any of a variety of biological phenomena characteristic of cancer cells, which may vary depending on the type of cancer. Cancer phenotypes are typically identified by abnormalities in aspects such as cell growth or proliferation (e.g., uncontrolled growth or proliferation), cell cycle regulation, cell mobility, cell-cell interactions or metastasis.
[0103] By reserving the right to limit or exclude any individual member of any such group, including any subrange or combination of subranges within that group, such members may be claimed as a range or in any similar manner, less than the full measure of the present disclosure may be claimed for any reason. In addition, by reserving the right to limit or exclude any individual substituent, analog, compound, ligand, structure or group thereof or any member of a claimed group, less than the full measure of the present disclosure may be claimed for any reason.
[0104] Throughout this disclosure, various patents, patent applications, and publications are cited. The disclosures of these patents, patent applications, and publications are incorporated herein by reference in their entirety to more fully describe the state of the art known to those skilled in the art as of the date of this disclosure. In the event of any inconsistency between the cited patents, patent applications, and publications and this disclosure, the present disclosure shall prevail.
[0105] II. Antigen Binding Units, Compositions, and Methods
[0106] In one embodiment, the present disclosure provides an antigen binding unit comprising a light chain complementarity determining region (CDR) and a heavy chain CDR.
[0107] In another embodiment, the present disclosure provides an antigen binding unit comprising a light chain CDR and a heavy chain CDR, wherein the antigen binding unit specifically binds to CCR8 and / or blocks CCL1 from binding to CCR8.
[0108] In yet another embodiment, the present disclosure provides an antigen binding unit comprising a light chain CDR and a heavy chain CDR, and a crystallizable fragment (Fc) region operably linked to the antigen binding unit, wherein the antigen binding unit specifically binds to CCR8 and / or blocks CCL1 from binding to CCR8.
[0109] In yet another embodiment, the present disclosure provides an antigen binding unit comprising a light chain CDR and a heavy chain CDR, and a crystallizable fragment (Fc) region, wherein the Fc region comprises a mutation at at least one amino acid position and is operably linked to the antigen binding unit; wherein the antigen binding unit specifically binds to CCR8 and / or blocks CCL1 from binding to CCR8, and wherein the mutation in the Fc region enhances antibody-dependent cellular cytotoxicity (ADCC).
[0110] In some embodiments, the crystallizable fragment (Fc) region comprises at least a portion of a human immunoglobulin constant region (Fc) with or without any mutations. In some embodiments, the mutation comprises an S239D mutation, an I332E mutation, an L235V mutation, an F243L mutation, an R292P mutation, a Y300L mutation, a P396L mutation, or a combination thereof.
[0111] In some embodiments, the crystallizable fragment (Fc) region comprises at least a portion of human IgG1 (Fc) without mutations (SEQ ID NO: 119), or with mutations including S239D / I332E (SEQ ID NO: 120) or L235V / F243L / R292P / Y300L / P396L (SEQ ID NO: 121), wherein the mutations in the Fc region enhance antibody-dependent cellular cytotoxicity (ADCC).
[0112] In some embodiments, the crystallizable fragment (Fc) region comprises an amino acid sequence selected from SEQ ID NOs: 119-121:
[0113] SEQ ID NO:119
[0114] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
[0115] SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL
[0116] LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
[0117] REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
[0118] YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
[0119] SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0120] SEQ ID NO:120
[0121] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
[0122] SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL
[0123] LGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
[0124] REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQV
[0125] YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
[0126] SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0127] SEQ ID NO:121
[0128] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
[0129] SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL
[0130] VGGPSVFLLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
[0131] PEEQYNSTLRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
[0132] TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPLVLDSDGSFFLYS
[0133] KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0134] In any embodiment disclosed herein, the antigen binding unit comprises a light chain CDR (labeled as vL or LC in Tables 1-3). The light chain CDR can be the complementary determining region of the light chain of the antigen binding unit. The light chain CDR may comprise a continuous sequence of amino acid residues, or two or more continuous sequences of amino acid residues separated and optionally flanked by a non-complementary determining region (such as a framework region). In some examples, the light chain CDR comprises two or more light chain CDRs, which may be referred to as light chain CDR-1, CDR-2, etc. In a favorable example, the light chain CDR comprises three light chain CDRs, which may be referred to as light chain CDR-1, light chain CDR-2, and light chain CDR-3, respectively. In some examples, a group of CDRs present in a universal light chain may be collectively referred to as light chain CDRs.
[0135] In other embodiments, the antigen binding unit comprises a heavy chain CDR (labeled as vH or HC in Tables 1-3). The heavy chain CDR can be the complementary determining region of the heavy chain of the antigen binding unit. The heavy chain CDR may comprise a continuous sequence of amino acid residues, or two or more continuous sequences of amino acid residues separated and optionally flanked by a non-complementary determining region (such as a framework region). In some examples, the heavy chain CDR comprises two or more heavy chain CDRs, which may be referred to as heavy chain CDR-1, CDR-2, etc. In a favorable example, the heavy chain CDR comprises three heavy chain CDRs, which may be referred to as heavy chain CDR-1, heavy chain CDR-2, and heavy chain CDR-3, respectively. In some examples, a group of CDRs present in a common heavy chain may be collectively referred to as heavy chain CDRs.
[0136] In other embodiments, the subject antigen binding unit specifically binds to CCR8. As used herein, CCR8 can also refer to an ortholog, homolog, codon optimized form, truncated form, fragment form, mutant form or any other known derivative form of the CCR8 sequence. For example, CCR8 can be human CCR8, mouse CCR8 or cynomolgus monkey CCR8.
[0137] Binding specificity can be determined by complementary determining region or CDR (such as light chain CDR or heavy chain CDR). In many cases, binding specificity is determined by light chain CDR and heavy chain CDR. Compared with other reference antigens, a given combination of heavy chain CDR and light chain CDR provides a given binding pocket that gives greater affinity and / or specificity to CCR8.
[0138] The binding of antigen binding unit to CCR8 can be characterized or expressed by any method known in the art. For example, binding can be characterized by binding affinity, and binding affinity can be the intensity of the interaction between antigen binding unit and antigen. Binding affinity can be determined by any method known in the art, such as in vitro binding assay. For example, the binding affinity of the antigen binding unit disclosed herein can be determined in an in vitro binding assay using cells expressing CCR8. The binding affinity of the subject's antigen binding unit can be represented by Kd, which is the equilibrium dissociation constant between the antibody and its respective antigen. In some cases, the antigen binding unit disclosed herein specifically binds to CCR8 with a Kd in the range of about 10 μM to about 1 fM. For example, the antigen binding unit can be less than about 10 μM, 1 μM, 0.1 μM, 10nM, 1nM, 0.1nM, 10pM, 1pM, 0.1pM, 10fM, 1fM, 0.1fM or less than 0.1fM Kd specific binding CCR8.
[0139] In some embodiments, the antigen binding unit reduces or even prevents the binding of CCR8 to CCL1, thereby inhibiting the recruitment of regulatory T cells and / or the recruitment of signaling factors such as β-arrestin, etc.
[0140] In some embodiments, the antigen binding unit includes light chain CDR and heavy chain CDR. The subject's antigen binding unit may include any sequence listed in Table 1. In addition, or alternatively, the subject's antigen binding unit may include a sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to any sequence listed in Tables 1-3, including any range (e.g., 60%-85%) with these values as endpoints.
[0141] In some embodiments, the antigen binding unit comprises a light chain CDR and a heavy chain CDR, wherein the light chain CDR or heavy chain CDR comprises a LC-CDR and a HC-CDR, respectively, which are selected from any combination of the light chain CDR (vL or LC) or heavy chain CDR (vH or HC) sequences listed in Tables 1 and 2.
[0142] Table 1: Variable region amino acid sequences and CDR definitions using the Kabat nomenclature
[0143]
[0144]
[0145]
[0146]
[0147]
[0148] Table 2: Variable region amino acid sequences
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157] Table 3: Amino acid sequences defined by the Kabat nomenclature CDR
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164] In some embodiments, the subject antigen binding unit is a monoclonal antigen binding unit, a polyclonal antigen binding unit, a humanized antigen binding unit, a chimeric antigen binding unit, a monovalent antigen binding unit, a multivalent antigen binding unit, a bispecific antigen binding unit, or any combination thereof. The antigen binding unit can take a variety of forms, including but not limited to: scFv, Fab', single-chain Fab (scFab'), Fd or F(ab')2, sFC, Fv and ccFv. Such antigen binding units can be generated from whole immunoglobulins by cleavage of ricin, pepsin, papain or other proteases.
[0165] In addition, antigen binding units can be designed using recombinant immunoglobulin technology. For example, an "Fv" immunoglobulin can be produced by connecting a variable light chain region to a variable heavy chain region via a peptide linker. For example, the peptide linker can be polyglycine or another sequence that does not form an α-helix or β-sheet motif. Fv can also be prepared that includes a stabilized V H and V L Disulfide bonds between regions are described in U.S. Pat. No. 6,147,203, the contents of which are incorporated herein by reference in their entirety. Any of these antigen binding units may be used. In some aspects, the antigen binding unit may be a complete immunoglobulin having two light chains paired with two heavy chains.
[0166] The antigen binding unit may be a heteromultimer comprising a light chain polypeptide and a heavy chain polypeptide. Examples of antigen binding units include, but are not limited to: (i) a ccFv fragment stabilized by a heterodimer sequence disclosed in U.S. Pat. No. 6,833,441, the contents of which are incorporated herein in their entirety; (ii) any other monovalent and multivalent molecule comprising at least one ccFv fragment as described herein; (iii) a Fab fragment consisting of VL, VH, CL and CH1 domains; (iv) a Fd fragment consisting of VH and CH1 domains; (v) a Fv fragment consisting of the VL and VH domains of a single antibody arm; (vi) a F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bond at the hinge region; and (vii) a bispecific antibody.
[0167] By injecting the antigen composition into the production animal, polyclonal antibodies can be produced by standard protocols. For example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. When the whole protein or a larger portion of the protein is used, antibodies can be produced by immunizing the production animal with the protein and a suitable adjuvant (e.g., Freund's adjuvant, Freund's complete adjuvant, oil-in-water emulsion, etc.). When a smaller peptide is used, it is advantageous to conjugate the peptide to a larger molecule to prepare an immunostimulatory conjugate. Commonly used conjugated proteins commercially available for this purpose include bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH). In order to produce antibodies against specific epitopes, peptides derived from the full sequence can be used. Alternatively, in order to produce antibodies against relatively short peptide portions of a protein target, if the polypeptide is combined with a carrier protein (e.g., ovalbumin, BSA or KLH), an excellent immune response can be elicited.
[0168] Polyclonal or monoclonal antigen binding units or antibodies can be produced from animals that have been genetically modified to produce human immunoglobulins. Transgenic animals can be produced by initially producing "knockout" animals that do not produce natural animal antibodies, and stably transforming the animals (e.g., by using human artificial chromosomes) with human antibody loci. In this case, the animals can only produce human antibodies. The technology for producing such animals and obtaining antibodies therefrom is described in U.S. Patents 6,162,963 and 6,150,584, the contents of which are incorporated herein by reference in their entirety. Such antibodies can be referred to as human xenogeneic antibodies.
[0169] Alternatively, the antigen binding units can be generated from a phage library containing human variable regions. See U.S. Pat. No. 6,174,708, the contents of which are incorporated herein by reference in their entirety.
[0170] In some aspects of any of the embodiments disclosed herein, the antigen binding unit is produced by a hybridoma. For example, the antigen binding unit disclosed herein can be produced by a hybridoma selected from a group of hybridomas expressing one of the antigen binding units listed in Table 1.
[0171] For monoclonal antigen binding unit or monoclonal antibody, hybridoma can be formed by separating stimulated immune cells, such as immune cells from the spleen of inoculated animals. Then, these cells can be fused with immortal cells, such as myeloma cells or transformed cells, and these cells can be infinitely replicated in cell culture, thereby producing immortal immunoglobulin secreting cell lines. The immortal cell line utilized can be selected as lacking the enzyme necessary for utilizing some nutrition. Many such cell lines (such as myeloma) are well known to those skilled in the art, and include, for example, thymidine kinase (TK) or hypoxanthine guanine phosphoribosyl transferase (HGPRT). These defects allow to select fused cells according to the ability of fused cells to grow on, for example, hypoxanthine aminopterin thymidine culture medium (HAT).
[0172] Furthermore, antigen binding units can be produced by genetic engineering. Humanized, chimeric or xenogeneic human antigen binding units are contemplated, which produce less immune response when administered to humans.
[0173] The antigen binding units disclosed herein may have a reduced tendency to induce an undesirable immune response (e.g., anaphylactic shock) in humans, and may also exhibit a reduced tendency to elicit an immune response that will prevent repeated doses of antibody therapeutics or imaging agents (e.g., human-anti-mouse antibody "HAMA" responses). Such antigen binding units include, but are not limited to, humanized, chimeric, or xenogeneic human antigen binding units.
[0174] Chimeric antigen binding units or chimeric antibodies can be prepared, for example, by recombinant methods, by combining mouse variable light and heavy chain regions (VL and VH) obtained from mouse (or other animal derived) hybridoma clones with human constant light and heavy chain regions, to prepare antibodies having mainly human domains. The production of such chimeric antibodies is well known in the art, and can be achieved by standard methods (which are described in, for example, U.S. Pat. No. 5,624,659, the contents of which are incorporated herein by reference in their entirety).
[0175] The term "humanization" applicable to non-human (e.g., rodent or primate) antibodies is a hybrid immunoglobulin, an immunoglobulin chain or a fragment thereof, which comprises a minimal sequence derived from a non-human immunoglobulin. In most cases, a humanized antibody is a human immunoglobulin (receptor antibody), wherein the residues from the complementary determining region (CDR) of the receptor are replaced by residues from the CDR of a non-human species (donor antibody), such as mice, rats, rabbits or primates, which have desired specificity, affinity and ability. In some cases, the Fv framework region (FR) residues of a human immunoglobulin are replaced by corresponding non-human residues. In addition, a humanized antibody may include residues that are neither found in the receptor antibody nor in the CDR or framework sequences imported. These modifications are carried out to further refine and optimize antibody performance and minimize immunogenicity when introduced into the human body. In some examples, a humanized antibody will comprise substantially all of at least one (usually two) variable domains, wherein all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin sequence. A humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin, such as human IgG1.
[0176] Humanized antibodies can be designed to contain human-like immunoglobulin domains and only contain complementary determining regions of animal-derived antibodies. This can be achieved by carefully examining the sequence of the hypervariable loops of the variable regions of the monoclonal antigen binding unit or monoclonal antibodies and matching them with the structure of the human antigen binding unit or human antibody chains. For example, see U.S. Pat. No. 6,187,287, the contents of which are incorporated herein by reference in their entirety.
[0177] The method of humanizing non-human antibodies is well known in the art. "Humanized" antibodies refer to antibodies that change at least part of the sequence from its initial form to be more like human immunoglobulin. In some versions, heavy (H) chain and light (L) chain constant (C) region are replaced by human sequences. This can be a fusion polypeptide comprising a variable (V) region and a heterologous immunoglobulin C region. In some versions, the complementary determining region (CDR) comprises a non-human antibody sequence, and the V framework region has also been converted to a human sequence. For example, see EP0,329,400. In some versions, the V region is humanized by designing a consensus sequence in the human and mouse V region and converting residues that are different from the consensus sequence outside the CDR.
[0178] In principle, framework sequences from humanized antibodies can serve as templates for CDR grafting; however, it has been demonstrated that direct replacement of CDRs into such frameworks results in a significant loss of binding affinity to the antigen. Glaser et al. (1992) J. Immunol. 149:2606; Tempest et al. (1992) Biotechnology 9:266; and Shalaby et al. (1992) J. Exp. Med. 17:217. The higher the homology of a human antibody (HuAb) to the original murine antibody (muAb), the less likely it is that the human framework will introduce distortions in the murine CDRs that could reduce affinity. Based on sequence homology searches against antibody sequence databases, HuAb IC4 provides good framework homology to muM4TS.22, although other highly homologous HuAbs are also suitable, particularly the kappa L chain from human subgroup I or the H chain from human subgroup III. Kabat et al. (1987). Various computer programs such as ENCAD (Levitt et al. (1983) (1983) J. Mol. Biol. 168: 595) can be used to predict the ideal sequence of the V region. HuAbs with different variable (V) regions are contemplated. It is within the skill of those skilled in the art to determine the appropriate V region sequence and optimize these sequences. Methods for obtaining antibodies with reduced immunogenicity are also described in U.S. Patents US, 5270,202 and EP699,755.
[0179] Humanized antibodies can be prepared by using the three-dimensional model of the parental and humanized sequences to analyze the process of parental sequences and various conceptual humanized products. The three-dimensional immunoglobulin model is familiar to those skilled in the art. Computer programs can be used to illustrate and display the possible three-dimensional conformational structure of selected candidate immunoglobulin sequences. Inspection of these displays allows analysis of the possible role of residues in the function of candidate immunoglobulin sequences, i.e., analysis of the residues that affect the ability of candidate immunoglobulins to bind their antigens. In this way, FR residues can be selected and combined from consensus sequences and imported sequences to achieve desired antibody properties, such as improving affinity to the target antigen.
[0180] The process of humanizing the subject's antigen binding unit can be as follows. Based on the homology, typical structure and physical properties of the human antibody germline used for transplantation, the most suitable germline receptor heavy chain and light chain variable region are selected. The mVH / VL is subjected to computer modeling relative to the hVH / VL of the transplantation, and a prototype humanized antibody sequence is generated. If the modeling shows that a framework reverse mutation is required, a second variant with an indication FW change is generated. The DNA fragments encoding the selected germline framework and mouse CDR are synthesized. The synthetic DNA fragments are subcloned into an IgG expression vector, and the sequence is confirmed by DNA sequencing. The humanized antibody is expressed in a cell (such as 293F), and the protein is tested, for example, in an MDM phagocytosis assay and an antigen binding assay. The humanized antigen binding unit is compared with the parental antigen binding unit in terms of antigen binding affinity, for example, by FACS on cells expressing the target antigen. If the affinity is more than 2 times lower than the parental antigen binding unit, a second round of humanized variants can be produced and tested as described above.
[0181] As mentioned above, antigen binding units can be "monovalent" or "multivalent". The former has one binding site per antigen binding unit, while the latter contains more than one binding site that can bind to the same or different types of antigens. Depending on the number of binding sites, an antigen binding unit can be bivalent (having two antigen binding sites), trivalent (having three antigen binding sites), tetravalent (having four antigen binding sites), etc.
[0182] Multivalent antigen binding units can be further classified according to their binding specificity. A "monospecific" antigen binding unit is a molecule that can bind to one or more of the same antigens. A "multispecific" antigen binding unit is a molecule that has binding specificity to at least two different antigens. Although such a molecule usually only binds to two different antigens (i.e., a bispecific antigen binding unit), when used herein, antibodies with additional specificity such as trispecific antibodies are included in this expression. The present disclosure also provides multispecific antigen binding units. A multispecific antigen binding unit is a multivalent molecule that can bind to at least two different antigens. Preferred multispecific antigen binding units are bispecific and trispecific molecules that show binding specificity to two and three different antigens, respectively.
[0183] In some embodiments, the antigen binding unit is a bispecific antigen binding unit, wherein the antigen binding unit specifically binds to CCR8 and a second antigen. In some instances, the second antigen is combined with CCR8 from different species. For example, the bispecific antigen binding unit can bind to human CCR8 and cynomolgus monkey CCR8. Alternatively, the bispecific antigen binding unit can cover its binding properties for binding, such as binding to human CCR8, and its blocking properties for blocking, such as blocking the binding of CCL1 to human CCR88. Other suitable second antigens include, but are not limited to, tumor cell antigens, immune cell antigens, cytotoxic trigger molecules, toxins, fibrinolytic agents, cell surface receptors, infectious disease targets, vaccine adjuvants, diagnostic agents, detection molecules, and reporter molecules.
[0184] Polynucleotides and vectors
[0185] In some embodiments, there is provided an isolated nucleic acid encoding any antigen binding unit disclosed herein. In another embodiment, there is provided a vector comprising a nucleic acid sequence encoding any antigen binding unit disclosed herein. In some embodiments, there is provided an isolated nucleic acid encoding the light chain CDR and heavy chain CDR of an antigen binding unit disclosed herein.
[0186] The subject antigen binding unit can be prepared by recombinant DNA technology, synthetic chemistry technology or its combination.For example, the sequence of the required composition (including light chain CDR and heavy chain CDR) of the encoding antigen binding unit is usually assembled and cloned into an expression vector using standard molecular techniques known in the art.These sequences can be assembled from other vectors of the desired protein sequence, from the fragments produced from PCR using respective template nucleic acids or by the synthetic oligonucleotides of the desired sequence of encoding.Expression systems can be created by transfecting suitable cells with expression vectors comprising the target antigen binding unit.
[0187] Nucleotide sequences corresponding to different regions of the light chain or heavy chain of existing antibodies can be easily obtained and sequenced using conventional techniques (including but not limited to hybridization, PCR and DNA sequencing). The hybridoma cells that produce monoclonal antibodies are the preferred source of antibody nucleotide sequences. Hybridoma cells that produce a large number of monoclonal antibody arrays can be obtained from public or private repositories. The largest preservation agency is the American Type Culture Collection (atcc.org), which provides a variety of fully characterized hybridoma cell lines. Alternatively, antibody nucleotides can be obtained from immune or non-immune rodents or humans, and form organs such as spleen and peripheral blood lymphocytes. Specific techniques suitable for extracting and synthesizing antibody nucleic acids are described in Orlandi et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Larrick et al. (1989) Biochem. Biophys. Res. Commun. 160:1250-1255; Sastry et al. (1989) Proc. Natl. Acad. Sci., USA 86:5728-5732; and U.S. Pat. No. 5,969,108.
[0188] The polynucleotide encoding the antigen binding unit can also be modified, for example, by replacing the homologous non-human sequence with the coding sequence of the human heavy and light chain constant regions. In this way, a chimeric antibody retaining the binding specificity of the original antigen binding unit is prepared.
[0189] It is also understood that polynucleotides include those encoding functional equivalents of the exemplified polypeptides and fragments thereof. Functionally equivalent polypeptides include those that enhance, reduce, or do not significantly affect the properties of the polypeptides encoded thereby. Functional equivalents can be polypeptides with conservative amino acid substitutions, analogs including fusions, and mutants.
[0190] Due to the degradation of the genetic code, there may be considerable changes in the nucleotides of the antigen binding unit coding sequence and the sequences suitable for constructing polynucleotides and vectors. Sequence variants may have modified DNA or amino acid sequences, one or more substitutions, deletions or additions, the net effect of which is to maintain the desired antigen binding activity. For example, various substitutions can be made in the coding region, which either do not change the encoded amino acid or produce conservative changes. These substitutions are covered in the disclosure of this article. Conservative amino acid substitutions include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Although conservative substitutions do effectively change one or more amino acid residues contained in the polypeptide to be produced, it is expected that these substitutions will not interfere with the antigen binding activity of the antigen binding unit to be produced. Nucleotide substitutions that do not change the encoded amino acid residues can be used to optimize gene expression in different systems. Suitable substitutions are known to those skilled in the art, and are, for example, performed to reflect the preferred codon usage in the expression system.
[0191] If necessary, the recombinant polynucleotide may include heterologous sequences that contribute to the expression and purification of the detection gene product. Examples of such sequences are known in the art, including those encoding reporter proteins, such as β-galactosidase, β-lactamase, chloramphenicol acetyltransferase (CAT), luciferase, green fluorescent protein (GFP) and derivatives thereof. Other heterologous sequences that contribute to purification may encode epitopes, such as Myc, HA (derived from influenza virus hemagglutinin), His-6, FLAG or the Fc portion of an immunoglobulin, glutathione S-transferase (GST) and maltose binding protein (MBP).
[0192] The polynucleotides disclosed herein can be conjugated with the above-mentioned various chemical functional parts. Common parts include markers capable of producing detectable signals, signal peptides, reagents that enhance immunoreactivity, reagents that promote conjugation with solid supports, vaccine carriers, biological response modifiers, paramagnetic markers and drugs. The parts can be covalently linked polynucleotides recombined or by other means known in the art.
[0193] The polynucleotide may contain additional sequences, such as additional coding sequences within the same transcription unit, control elements such as promoters, ribosome binding sites and polyadenylation sites, additional transcription units under the control of the same or different promoters, sequences that allow cloning, expression and transformation of host cells, and any such constructs suitable for providing embodiments.
[0194] Polynucleotides can be obtained using chemical synthesis, recombinant cloning methods, PCR or any combination thereof. Methods for chemical polynucleotide synthesis are well known in the art and need not be described in detail herein. Those skilled in the art can use the sequence data provided herein to obtain desired polynucleotides by using a DNA synthesizer or ordering from a commercial service.
[0195] The polynucleotides comprising the desired sequence can be inserted into a suitable vector, which can in turn be introduced into a suitable host cell for replication and amplification. Thus, a variety of vectors comprising one or more polynucleotides are provided. A selective library of expression vectors is also provided, the expression vector comprising at least one vector encoding an antigen binding unit disclosed herein.
[0196] The vector usually contains transcription or translation control sequences required for expressing the antigen binding unit. Suitable transcription or translation control sequences include, but are not limited to, replication origin, promoter, enhancer, repressor binding region, transcription start site, ribosome binding site, translation start site, and transcription and translation termination sites.
[0197] The choice of promoter will depend largely on the host cell into which the vector is introduced. Promoters commonly associated with the desired light or heavy chain genes may also be used, provided that such control sequences are compatible with the host cell system. Cell-specific or tissue-specific promoters may also be used. A large number of tissue-specific promoters have been described and used by those skilled in the art. Exemplary promoters that work in selective animal cells include hepatocyte-specific promoters and myocardial-specific promoters. Depending on the choice of the recipient cell type, those skilled in the art will know other suitable cell-specific or tissue-specific promoters that are suitable for constructing expression vectors.
[0198] Using known molecular cloning or genetic engineering techniques, appropriate transcription control sequences, enhancers, terminators or any other genetic elements known in the art can be integrated in an operative relationship, optionally in addition to the complete selective fusion gene to be expressed. In addition to the above elements, the vector can contain a selective marker (e.g., a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector), although such a marker gene can be carried on another polynucleotide sequence introduced into the host cell together.
[0199] Polynucleotides and vectors have several specific uses. For example, they can be used to produce expression systems for antigen binding units. Such polynucleotides can be used as primers to achieve amplification of desired polynucleotides. In addition, polynucleotides can also be used in pharmaceutical compositions, including vaccines, diagnostics, and drugs.
[0200] The host cells can be used, inter alia, as a repository for subject polynucleotides, vectors, or as a vehicle for producing and screening desired antigen-binding units based on their antigen-binding specificity.
[0201] Therefore, a method for identifying an antigen binding unit that has an immunoreaction with a desired antigen is provided. This method may include the following steps: (a) preparing a genetic diversity library of antigen binding units, wherein the library comprises at least one subject antigen binding unit; (b) contacting the library of antigen binding units with a desired antigen; (c) detecting the specific binding between the antigen binding unit and the antigen, thereby identifying an antigen binding unit that has an immunoreaction with the desired antigen.
[0202] The ability of an antigen binding unit to specifically bind to a desired antigen can be tested by various well-established procedures in the art. See Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratories, New York; Gherardi et al. (1990) J. Immunol. Meth. 126: 61-68. Typically, an antigen binding unit that exhibits a desired binding specificity can be directly detected by an immunoassay, for example, by reacting a labeled antigen binding unit with an antigen fixed on a solid support or matrix. Typically, the matrix to which the antigen is attached is made of a material that exhibits low levels of nonspecific binding during an immunoassay. Exemplary solid supports are made of one or more of the following materials: plastic polymers, glass, cellulose, nitrocellulose, semiconductive materials, and metals. In some instances, the matrix is a culture dish, a chromatographic bead, a magnetic bead, etc.
[0203] For this solid phase assay, unreacted antigen binding units are removed by washing. However, in liquid phase assay, unreacted antigen binding units are removed by some other separation techniques (such as filtration or chromatography). After antigen is bound to the antigen binding units of labeling, the amount of the labeling of combination is determined. A variant of this technology is competitive assay, in which antigen is bound to saturation with the original binding molecule. When the colony of subject's antigen binding units is introduced into complex, only those showing higher binding affinity will be able to compete, and therefore keep combined with antigen.
[0204] Alternatively, specific binding to a given antigen can be assessed by cell sorting, which involves presenting the desired antigen on the cells to be sorted, then labeling the target cells with an antigen binding unit bound to a detectable agent, and then separating the labeled cells from the unlabeled cells in a cell sorter. A sophisticated method for cell separation is fluorescence activated cell sorting (FACS). Cells traveling in a single file in a thin stream pass through a laser beam, and the fluorescence of each cell bound by a fluorescently labeled antigen binding unit is measured.
[0205] Subsequent analysis of the eluted antigen binding units may involve protein sequencing for describing the amino acid sequences of light and heavy chains. Based on the derived amino acid sequence, the cDNA encoding the antibody polypeptide may then be obtained by a recombinant cloning method comprising PCR, library screening, homology searches in existing nucleic acid databases, or any combination thereof. Commonly used databases include, but are not limited to, GenBank, EMBL, DDBJ, PDB, SWISS-PROT, EST, STS, GSS, and HTGS.
[0206] When the library of antigen binding units is displayed on phage or bacterial particles, it is preferably selected using affinity chromatography. The method is usually to bind the phage antigen binding unit library to the biotinylated antigen in the plate, column matrix, cell or solution coated with the antigen, and then capture. The phage or bacteria bound to the solid phase are washed and then eluted with a soluble hapten, acid or alkali. Alternatively, increasing the antigen concentration can be used to separate the antigen binding units from the affinity matrix. For some antigen binding units with extremely high affinity or avidity with the antigen, as described in WO92 / 01047, effective elution may require high pH or gentle reducing solution.
[0207] The efficiency of selection may depend on a combination of several factors, including the dissociation kinetics during washing, and whether multiple antigen-binding units on a single phage or bacterium can bind to the antigen on the solid support simultaneously. For example, antibodies with fast dissociation kinetics (and weak binding affinity) can be retained by using short washes, multivalent displays, and high coating density of antigen on the solid support. Conversely, antigen-binding units with slow dissociation kinetics (and good binding affinity) can be favored by using long washes, monovalent phage, and low antigen coating density.
[0208] Where necessary, the library of antigen binding units can be pre-selected against unrelated antigens to counter-select undesirable antigen binding units. The library can also be pre-selected against related antigens to isolate, for example, anti-idiotypic antigen binding units.
[0209] Host cells
[0210] In some embodiments, the present disclosure provides a host cell expressing any of the antigen binding units disclosed herein.The subject host cell typically comprises a nucleic acid encoding any of the antigen binding units disclosed herein.
[0211] In one embodiment, a host cell transfected with the above-mentioned polynucleotide, vector or vector library is provided. The vector can be introduced into a suitable prokaryotic or eukaryotic cell by any of a variety of suitable methods, including electroporation, microprojectile bombardment; lipid infection, infection (wherein the vector is combined with an infectious agent), transfection using calcium chloride, rubidium chloride, calcium phosphate, DEAE dextran or other substances. The choice of method for introducing the vector generally depends on the characteristics of the host cell.
[0212] For most animal cells, any of the above methods are suitable for vector delivery. Preferred animal cells are vertebrate cells, preferably mammalian cells, which can express exogenously introduced gene products in large quantities (e.g., at the milligram level). Non-limiting examples of preferred cells are NIH3T3 cells, COS, HeLa and CHO cells.
[0213] Once introduced into a suitable host cell, the expression of the antigen binding unit can be determined using any nucleic acid or protein assay known in the art. For example, the transcription mRNA of light chain CDR or heavy chain CDR, or the presence of the antigen binding unit, can be detected and / or quantified using a probe complementary to any region of the antigen binding unit polynucleotide by the following methods: conventional hybridization assays (e.g., Northern blot analysis), amplification procedures (e.g., RT-PCR), SAGE (U.S. Pat. No. 5,695,937) and array-based techniques (e.g., see U.S. Pat. No. 5,405,783, U.S. Pat. No. 5,412,087 and U.S. Pat. No. 5,445,934).
[0214] The expression of the vector can also be determined by examining the expressed antigen binding units. There are a variety of techniques in the art that can be used for protein analysis. They include, but are not limited to, radioimmunoassay, ELISA (enzyme-linked immunoradiometric assay), "sandwich" immunoassay, immunoradiometric assay, in situ immunoassay (using, for example, colloidal gold, enzyme or radioisotope labeling), Western blot analysis, immunoprecipitation assay, immunofluorescence assay and SDS-PAGE.
[0215] Preparation of antigen binding units
[0216] In some embodiments, a method for producing any antigen binding unit disclosed herein is provided. The method comprises culturing a host cell expressing the antigen binding unit under conditions suitable for expressing the antigen binding unit, and isolating the antigen binding unit expressed by the host cell.
[0217] The antigen binding units expressed can be separated using a variety of protein purification techniques known in the art. Typically, antigen binding units are separated from culture medium as secreted polypeptides, although when directly produced without a signal peptide, they can be recovered from host cell lysates or bacterial periplasm. If the antigen binding units are membrane-bound, they can be dissolved by suitable detergent solutions commonly used by those skilled in the art. The antigen binding units recovered can be further purified by the following methods: salt precipitation (e.g., with ammonium sulfate), ion exchange chromatography (e.g., on a cation or anion exchange column, run at neutral pH, and eluted with a step gradient that increases ionic strength), gel filtration chromatography (including gel filtration HPLC), and chromatographic analysis, such as protein A, protein G, hydroxyapatite, and anti-immunoglobulin, on a tag affinity column or on an affinity resin.
[0218] In addition, derivatized immunoglobulins with added chemical linkers, detectable moieties such as fluorescent dyes, enzymes, substrates, chemiluminescent moieties, specific binding moieties such as streptavidin, avidin or biotin, or drug conjugates can be used in the methods and compositions.
[0219] Also disclosed herein are antigen binding units conjugated to chemical functional moieties. Typically, the moiety is a marker capable of producing a detectable signal. These conjugated antigen binding units can be used, for example, in detection systems, such as quantification of tumor burden, imaging of metastatic lesions, and tumor imaging. Such markers are known in the art, including but not limited to: radioisotopes, enzymes, fluorescent compounds, chemiluminescent compounds, bioluminescent compounds, substrate cofactors, and inhibitors. See examples of teaching the application of such markers, U.S. Patents US3,817,837; US3,850,752; US3,939,350; US3,996,345; US4,277,437; US4,275,149; and US4,366,241. The moiety can be covalently linked to an antigen binding unit, recombinantly linked, or conjugated to an antigen binding unit by a second reagent (such as a second antibody, protein A, or a biotin-avidin complex).
[0220] Other functional parts include signal peptides, agents that enhance immunoreactivity, agents that promote binding to solid supports, vaccine carriers, biological response modifiers, paramagnetic markers and drugs. A signal peptide is a short amino acid sequence that directs newly synthesized proteins across a cell membrane, usually the endoplasmic reticulum in eukaryotic cells, and the inner or outer membranes of bacteria. The signal peptide can be located at the N-terminal portion of a polypeptide or the C-terminal portion of a polypeptide, and can be removed by an enzyme between biosynthesis and secretion of the polypeptide from a cell. Such a peptide can be incorporated into an antigen binding unit to allow secretion of the synthetic molecule.
[0221] Reagents that enhance immunoreactivity include, but are not limited to, bacterial superantigens. Reagents that promote binding to a solid support include, but are not limited to, biotin or avidin. Immunogenic carriers include, but are not limited to, any physiologically acceptable buffer. Biological response modifiers include cytokines, particularly tumor necrosis factor (TNF), interleukin-2, interleukin-4, granulocyte macrophage colony stimulating factor, and gamma-interferon.
[0222] Suitable drug moieties include antitumor agents. Non-limiting examples include: radioisotopes, vinca alkaloids such as vinblastine, vincristine and vindesine sulfate, doxorubicin, bleomycin sulfate, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, daunomycin hydrochloride, doxorubicin hydrochloride, etoposide, fluorouracil, lomustine, dichloromethyl diethylamine hydrochloride, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, pentostatin, pipobroman, procarbazine hydrochloride, streptozotocin, paclitaxel, thioguanine and uracil mustard.
[0223] Immunotoxins, including antigen binding units, can be produced by recombinant methods. The production of various immunotoxins is well known in the art, and methods thereof can be found, for example, in "Monoclonal Antibody-toxin Conjugates: Aiming the Magic Bullet," Thorpe et al. (1982) Monoclonal Antibodies in Clinical Medicine, Academic Press, pp. 168-190; Vitatta (1987) Science 238: 1098-1104; and Winter and Milstein (1991) Nature 349: 293-299. Suitable toxins include, but are not limited to, ricin, radionuclides, pokeweed antiviral proteins, Pseudomonas exotoxin A, diphtheria toxin, ricin A chain, fungal toxins such as restrictocin and phospholipases. Generally, see “Chimeric Toxins,” Olsnes and Pihl, Pharmac. Ther. 15:355-381 (1981); and “Monoclonal Antibodies for Cancer Detection and Therapy,” eds. Baldwin and Byers, pp. 159-179, 224-266, Academic Press (1985).
[0224] The chemical functional part can be prepared recombinantly, for example, by producing a fusion gene encoding an antigen binding unit and a functional part. Alternatively, the antigen binding unit can be chemically bound to the part by any of a variety of mature chemical procedures. For example, when the part is a protein, the connection can be through a heterogeneous bifunctional cross-linking agent, such as SPDP, carbodiimide glutaraldehyde, etc. The part can be covalently linked or conjugated by a second reagent (such as a second antibody, protein A or a biotin-avidin complex). Paramagnetic parts and their conjugation to antibodies are well known in the art. See, for example, Miltenyi et al. (1990) Cytometry 11: 231-238.
[0225] Use and treatment methods
[0226] CCR8-specific antigen binding units and pharmaceutical compositions comprising the same may find a wide range of applications, including but not limited to therapy and diagnosis.
[0227] In one embodiment, a pharmaceutical composition comprising a pharmaceutically acceptable excipient and any antigen binding unit disclosed herein is provided.
[0228] In another embodiment, a method of eliminating immune cells is provided, comprising contacting a population of immune cells with an effective amount of an antigen binding unit described herein.
[0229] In yet another embodiment, a method of eliminating immune cells is provided, comprising contacting a population of immune cells with an effective amount of a pharmaceutical composition described herein.
[0230] In embodiments, the immune cells are present in a subject, such as a human patient in need of treatment for a disease caused by abnormal immune cells and / or in need of removal of immune cells.
[0231] In embodiments, the immune cell is a regulatory T cell (Treg). Tregs can be present in a subject as resident tissue Tregs, for example, as a subpopulation of resident tumor infiltrating lymphocytes (TILs) in tumor tissue.
[0232] In embodiments, Tregs migrate, Tregs are eliminated by antibody-dependent cellular cytotoxicity (ADCC), or both.
[0233] In an embodiment, the method of treating cancer in a subject comprises administering to a subject in need thereof an effective amount of an antigen binding unit described herein, and optionally repeating the administering step for a period of time, for example, regularly once a day, once a week, once a month, for 1, 2, 3, 4, 5, 6 months, or until the subject is free of cancer.
[0234] In an embodiment, a method for treating cancer in a subject comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and any antigen binding unit disclosed herein. In an embodiment, the administering step is repeated according to a dosage regimen effective for treating cancer, as evidenced by the subject being free of cancer.
[0235] In embodiments, the subject is a human patient in need of anticancer treatment.Cancer can be a blood cancer or a solid tumor.Hematological cancer includes, but is not limited to, leukemia, lymphoma (such as non-Hodgkin's lymphoma) and myeloma.Solid tumors include, but are not limited to, colorectal cancer (CRC), spleen cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, melanoma, bile duct cancer, gallbladder cancer, thyroid cancer, sarcoma, kidney cancer, bladder cancer, uterine body cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, thymus cancer, liver cancer, testicular cancer, urothelial carcinoma, esophageal cancer and gastric tumor.In most cases, the effective amount is determined empirically by a test method well known in the art.In one aspect, the antigen binding unit is administered with a dosage of about 0.1mg / kg to about 10mg / kg body weight.
[0236] Treatment of cancer can be demonstrated by a reduction in the growth of cancer cells, including, but not limited to, a reduction in cancer cell proliferation, and a reduction in the rate at which non-cancerous cells become cancerous. Whether a reduction in cancer cell growth has been achieved can be readily determined using any known assay, including, but not limited to: [ 3 H]-thymidine incorporation; counting the number of cells over a period of time; detecting and / or measuring markers associated with AML, etc. Any of a variety of known cancer diagnostic assays can be used to assess whether a substance or a specific amount of a substance is effective in treating cancer, including but not limited to: biopsy, contrast radiographic studies, CAT scans, and detecting tumor markers associated with cancer in an individual's blood. The substance can be administered systemically or locally, usually systemically.
[0237] In embodiments, treatment of cancer may be demonstrated by a reduction in tumor volume. Tumor volume may be determined using any method known in the art. For example, tumor volume may be determined by measuring the tumor using a caliper. In this case, two dimensions of the tumor may be measured, and the formula V = 0.5 a x b may be used. 2 To determine tumor volume, where a and b are the first and second diameters. In some cases, the first diameter is the long diameter, or the larger diameter of the two diameters. In some cases, the second diameter is the short diameter, or the smaller diameter of the two diameters.
[0238] In embodiments, the treatment of cancer can be demonstrated by reducing tumor volume. In some cases, tumor volume is reduced with a percentage in the range of 1% to 100%. In some instances, tumor volume is reduced by about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%. In some instances, tumor volume is reduced by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0239] In embodiments, the effect comparison of the subject antigen binding unit and the reference antigen binding unit can be determined by calculating the anti-tumor efficacy. In this case, the tumor volume can be measured as described above. Alternatively, different parameters of tumor size or another appropriate feature of the tumor can be determined or measured. When using quantifiable features such as tumor volume, the anti-tumor effectiveness can be determined by using the formula T / C, where T is the selected measurement value (e.g., tumor volume) of the treatment group, and C is the selected measurement value (e.g., tumor volume) of the control group. The anti-tumor effectiveness can be determined within any desired time period, and can be determined using the mean value from any desired number of samples. The anti-tumor effectiveness can be expressed in numbers or percentages. In some instances, the anti-tumor effectiveness can be about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%. In some instances, the anti-tumor effectiveness may be at most 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. In some instances, the anti-tumor effectiveness may be at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
[0240] The compositions disclosed herein, such as antigen binding units and pharmaceutical compositions, can be administered using any medically appropriate procedure, such as intravascular (intravenous, intraarterial, intracapillary) administration, injection into lymph nodes, etc. Intravascular injection can be by intravenous or intraarterial injection. The effective amount of the composition administered to a particular patient depends on a variety of factors, some of which vary from patient to patient and can be determined empirically. The dosage of the composition will depend on the treatment regimen determined, the route of administration, the nature of the therapeutic agent, the sensitivity of the tumor to the therapeutic agent, etc. Utilizing LD 50 Animal data and other available information of antigen binding units disclosed herein, clinicians can determine the maximum safe dose of individuals according to the route of administration. For example, the intravenous administration dose may be greater than the local administration dose because the volume of the fluid to which the therapeutic composition is applied is larger. Similarly, compositions that are rapidly removed from the body can be administered at higher doses or with repeated doses to maintain therapeutic concentrations. Using common skills, competent clinicians will be able to optimize the dosage of a particular composition.
[0241] Methods for combined therapy are contemplated, wherein agents known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a subject antigen binding unit or a pharmaceutical composition comprising a subject antibody binding unit. In one embodiment, such therapy includes, but is not limited to, a combination of one or more antigen binding units of the present disclosure with a chemotherapeutic agent, a therapeutic antibody, and radiation therapy to provide a synergistic or additive therapeutic effect.
[0242] Many chemotherapeutic drugs are currently known in the art and can be used in combination with the subject's antigen binding unit. In some embodiments, the chemotherapeutic drug is selected from: mitotic inhibitors, alkylating agents, antimetabolites, chelating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors and anti-androgens.
[0243] Non-limiting examples are chemotherapeutic agents, cytotoxic agents, and non-peptide small molecules such as (imatinib mesylate), (bortezomib), Casodex (bicalutamide), (gefitinib) and doxorubicin and a range of chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquinone, meturedopa and uredopa; ethyleneimines and methylmelamines including hexamethylmelamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trihydroxymethylmelamine; nitrogen mustards such as chlorambucil, naphthyl mustard, chlorophosphamide, estramustine, ifosfamide, dichloromethyldiethylamine, methyl hydrochloride Oxygen mustard, melphalan, novembichin, phenylephrine, prednimustine, trofosfamide, uracil mustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics, such as aclacinomycins, actinomycins, authramycin, azaserine, bleomycin, actinomycin C, calicheamicin, carabicin, carminomycin, carmosin, Casodex TM), chromomycin, dactinomycin, daunorubicin, detorrubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin, mycophenolic acid, nogamycin, olive mycin, peplomycin, potfiromycin, puromycin, quelamycin, rhodorubicin, streptozocin, streptozotocin, tuberculocidin, ubenimex, netastatin, daurubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiabendazole , thioguanine; pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens, such as calutosterone, trotosterone propionate, thioandrostane, melastane, and testosterone lactone; antiadrenal drugs, such as aminoglutethimide, mitotane, and trilostane; folic acid supplements, such as folinic acid; acetylglucosyl esters; aldophosphamide glycoside; aminolevulinic acid; aminoacridine; bestrabucil; bisantrene; edatraxate; defofamine; colchicine; diaziquone; elformithine; elliptinium acetate acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguanidine; mitoxantrone; mopidarol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK.RTM; razoxane; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; polyurethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; cytarabine ("Ara-C"); cyclophosphamide; thiotepa; taxanes, such as paclitaxel (TAXOLTM, Bristol Myers Squibb Oncology, Princeton, NJ) and docetaxel (TAXORETM, Rhone Poulenc Rorer, Antony, France); retinoic acid; esperamicin; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included as suitable chemotherapeutic cell modulators are anti-hormonal agents that are used to modulate or inhibit hormonal effects on tumors, such as anti-estrogens, including, for example, tamoxifen, (Nolvadex. TM ), raloxifene, aromatase inhibitor 4(5)-imidazole, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone and toremifene (Fareston); and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; camptothecin-11 (CPT-11); the topoisomerase inhibitor RFS2000; and difluoromethylornithine (DMFO). If desired, the antigen binding units or pharmaceutical compositions of the present disclosure can be used in combination with commonly prescribed anticancer drugs, such as ABVD, AVICINE, abagovomab, acridinium carbamide, adecatumab, 17-N-allylamino-17-demethoxygeldanamycin, alpharadin, alvocidib, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, aminafide, anthracenedione, anti-CD22 immunotoxin, antineoplastic agent, antineoplastic herbal medicine, apaziquone, atiprimod, azathioprine, belotecan, bendamustine, BIBW 2992, biricodar, brostallicin, bryostatin, buthionine sulfoxide sulfoximine), CBV (chemotherapy), calyculin, cell cycle nonspecific antineoplastic agents, dichloroacetic acid, discodermolide, elsamitrucin, enocitabine, epothilone, eribulin, everolimus, exatecan, exisulind, ferruginol, forodesine, fosfostil, ICE chemotherapy, IT-101, imexon, imiquimod, indolecarbazole, irofulve n), laniquidar, larotaxel, lenalidomide, lucanthone, lurtotecan, mafosfamide, mitozolamide, nafoxidine, nedaplatin, olaparib, ortataxel, PAC-1, papaya, pixantrone, proteasome inhibitors, butterfly mycin, resiquimod, rubitecan, SN-38, salinosporamide A, sapacitabine, Stanford VV), swainsonine, talaporfin, tariquidar, tegafur, temozolomide, tesetaxel, triplatinium tetranitrate, tris(2-chloroethyl)amine, troxacitabine, uracil nitrogen mustard, vadimezan, vinflunine, ZD6126 or zosuquidar.
[0244] The present disclosure also relates to a method of combining the subject antigen binding unit or pharmaceutical composition provided herein with radiation therapy for inhibiting abnormal cell growth in mammals or treating hyperproliferative diseases. Techniques for administering radiation therapy are known in the art, and these techniques can be used for the combined treatments described herein.
[0245] Radiation therapy can be administered by a combination of one or more of several methods, including but not limited to: external beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy and permanent or temporary interstitial brachytherapy. The term "brachytherapy" as used herein refers to radiation therapy performed by inserting a spatially confined radioactive material into the body at or near a tumor or other proliferative tissue disease site. The term is intended to include, but is not limited to, exposure to radioisotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32 and Lu radioisotopes). Suitable radiation sources for use as cell regulators of the present disclosure include solids and liquids. As non-limiting examples, the radiation source can be a radionuclide, such as I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation or other therapeutic rays. The radioactive material can also be a fluid made from any solution of a radionuclide, such as a solution of I-125 or I-131, or a slurry of a suitable fluid containing small particles of solid radionuclides (such as Au-198, Y-90) can be used to produce a radioactive fluid. In addition, the radionuclide can be contained in a gel or radioactive microspheres.
[0246] The antigen binding unit or pharmaceutical composition of the present disclosure can be used in combination with a certain amount of one or more substances selected from the following: anti-angiogenesis agents, signal transduction inhibitors, anti-proliferation agents, glycolysis inhibitors or autophagy inhibitors.
[0247] Anti-angiogenic agents, such as MMP-2 (matrix metalloproteinase 2) inhibitors, MMP-9 (matrix metalloproteinase 9) inhibitors, and COX-11 (cyclooxygenase 11) inhibitors, can be used in combination with the antigen binding units of the present disclosure and the pharmaceutical compositions described herein. Anti-angiogenic agents include, for example, rapamycin, temsirolimus (CCI-779), everolimus (RAD001), sorafenib, sunitinib, and bevacizumab. Examples of useful COX-II inhibitors include Celebrex (Celebrex 9), and sutrinib. TMExamples of useful matrix metalloproteinase inhibitors are described in WO 96 / 33172 (published on October 24, 1996), WO 96 / 27583 (published on March 7, 1996), European patent application EP97304971.1 (filed on July 8, 1997), European patent application EP99308617.2 (filed on October 29, 1999), WO 98 / 07697 (published on February 26, 1998), WO 98 / 03516 (published on January 29, 1998), WO 98 / 34918 (published on August 13, 1998), WO 98 / 34915 (published on August 13, 1998), WO 98 / 33768 (published on August 6, 1998), WO 98 / 30566 (published on July 16, 1998), European Patent Publication EP606,046 (published on July 13, 1994), European Patent Publication EP931,788 (published on July 28, 1999), WO90 / 05719 (published on May 31, 1990), WO 99 / 52910 (published on October 21, 1999), WO99 / 52889 (published on October 21, 1999), WO99 / 29667 (published on June 17, 1999), PCT International Application PCT / IB98 / 01113 (filed on July 21, 1998), European Patent Application EP99302232.1 (filed on March 25, 1999), British Patent Application GB9912 961.1 (filed June 3, 1999), U.S. Provisional Application No. 60 / 148,464 (filed August 12, 1999), U.S. Pat. No. 5,863,949 (issued January 26, 1999), U.S. Pat. No. 5,861,510 (issued January 19, 1999), and European Patent Publication No. 780,386 (issued June 25, 1997), all of which are incorporated herein by reference in their entirety. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred are those that selectively inhibit MMP-2 and / or AMP-9 relative to other matrix metalloproteinases (e.g., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). Some specific examples of MMP inhibitors useful in the present disclosure are AG-3340, RO 32-3555, and RS13-0830.
[0248] Autophagy inhibitors include, but are not limited to, chloroquine, 3-methyladenine, hydroxychloroquine (PlaquenilTM), bafilomycin A1, 5-amino-4-imidazolecarboxamide ribose (AICAR), okadaic acid, autophagy-inhibiting algae toxins that inhibit type 2A or type 1 protein phosphatases, analogs of cAMP, and drugs that increase cAMP levels, such as adenosine, LY204002, N6 mercaptopurine ribose, and vinblastine. In addition, antisense RNA or siRNA that inhibits protein expression, including but not limited to ATG5 (which is associated with autophagy), can also be used.
[0249] In some embodiments, the antigen binding units and pharmaceutical compositions described herein are formulated or applied with a liquid or solid tissue barrier (also referred to as a lubricant). Examples of tissue barriers include, but are not limited to, polysaccharides, polysaccharides, biofilms (seprafilm), anti-adhesion membranes (interceed) and hyaluronic acid.
[0250] In some embodiments, the drug administered with the subject antigen binding unit includes: any suitable drug effectively delivered by inhalation, such as analgesics, such as codeine, dihydromorphine, ergotamine, fentanyl or morphine; angina preparations, such as diltiazem; anti-allergic drugs, such as cromoglycate, ketotifen or nedocromil; anti-infective drugs, such as cephalosporins, penicillins, streptomycin, sulfonamides, tetracyclines or pentamidine; antihistamines, such as methapyrine; anti-inflammatory drugs, such as beclomethasone, flunisolide, budesonide, tipredan, triamcinolone acetonide or fluticasone; cough suppressants, such as noscapine; bronchodilators, such as ephedrine, epinephrine, fenoterol, fluticasone, chloramphenicol ... formoterol, isoproterenol, isoproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, remiterol, salbutamol, salmeterol, terbutaline, isotharine, tulobuterol, metaproterenol, or (-)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzyl alcohol; diuretics such as amiloride; anticholinergics such as ipratropium, atropine, or oxytropine; hormones such as cortisone, hydrocortisone, or prednisolone; xanthines such as aminophylline, theophylline choline, theophylline lysine, or theophylline; and therapeutic proteins and peptides such as insulin or glucagon. It will be clear to those skilled in the art that, where appropriate, the drug is used in the form of a salt (e.g., as an alkali metal or amine salt or as an acid addition salt), or an ester (e.g., a lower alkyl ester) or a solvate (e.g., a hydrate) to optimize the activity and / or stability of the drug.
[0251] Other exemplary therapeutic agents that can be used in combination therapy include, but are not limited to, the above-mentioned agents, radiation therapy, hormone antagonists, hormones and their releasing factors, thyroid and antithyroid drugs, estrogens and progestins, androgens, adrenocorticotropic hormone; adrenocorticosteroids and their synthetic analogs; inhibitors of the synthesis and action of adrenocorticotropic hormones, insulin, oral hypoglycemic agents, and endocrine pancreatic pharmacology, agents that affect calcification and bone turnover: calcium, phosphate, parathyroid hormone, vitamin D, calcitonin, vitamins such as water-soluble vitamins, vitamin B complex, ascorbic acid, fat-soluble vitamins, vitamins A, K and E, as well as growth factors, cytokines, chemokines, muscarinic receptor agonists and antagonists; anticholinesterase drugs; agents that act at the neuromuscular junction and / or autonomic ganglia; catecholamines, sympathomimetics, and adrenergic receptor agonists or antagonists; and 5-hydroxytryptamine (5-HT, serotonin) receptor agonists and antagonists.
[0252] Therapeutic agents may also include agents for pain and inflammation, such as histamine and histamine antagonists, bradykinin and bradykinin antagonists, 5-hydroxytryptamine (serotonin), lipid substances produced by biotransformation of products of selective hydrolysis of membrane phospholipids, eicosanoids, prostaglandins, thromboxanes, leukotrienes, aspirin, nonsteroidal anti-inflammatory drugs, analgesics and antipyretics, drugs that inhibit the synthesis of prostaglandins and thromboxanes, selective inhibitors of inducible cyclooxygenase, selective inhibitors of inducible cyclooxygenase-2, endocrines, paracrine hormones, somatostatin, gastrin, cytokines that mediate the interaction of humoral and cellular immune responses, lipid-derived endocrines, eicosanoids, beta-adrenergic agonists, ipratropium, glucocorticoids, methylxanthines, sodium channel blockers, opioid receptor agonists, calcium channel blockers, membrane stabilizers, and leukotriene inhibitors.
[0253] Other therapeutic agents contemplated herein include diuretics, vasopressins, drugs that affect renal water retention, rennet, angiotensin, drugs used to treat myocardial ischemia, antihypertensive drugs, angiotensin converting enzyme inhibitors, beta-adrenergic receptor antagonists, drugs used to treat hypercholesterolemia, and drugs to treat dyslipidemia.
[0254] Other therapeutic agents contemplated include: drugs for controlling gastric acid, drugs for treating peptic ulcers, drugs for treating gastroesophageal reflux disease, prokinetics, antiemetics, drugs for irritable bowel syndrome, drugs for diarrhea, drugs for constipation, drugs for inflammatory bowel disease, drugs for biliary tract disease, agents for pancreatic disease. Therapeutic agents for treating protozoan infections, drugs for treating malaria, amebiasis, giardiasis, trichomoniasis, trypanosomiasis and / or leishmaniasis, and / or drugs for chemotherapy of helminthiasis. Other therapeutic agents include: antimicrobial agents, sulfonamides, sulfamethoxazole-trimethoprim-quinolone drugs, urinary tract infection agents, penicillins, cephalosporins and other beta-lactam antibiotics, drugs containing aminoglycosides, protein synthesis inhibitors, drugs for chemotherapy of tuberculosis, Mycobacterium avium complex and leprosy, antifungal agents, antiviral agents including non-retroviral agents and antiretroviral agents.
[0255] Examples of therapeutic antibodies that can be combined with the antigen binding units of the present disclosure include, but are not limited to, anti-receptor tyrosine kinase antibodies (cetuximab, panitumumab, trastuzumab), anti-CD20 antibodies (rituximab, tositumomab), immune checkpoint inhibitors (such as anti-PD-1, anti-PD-L1 antibodies and anti-CTLA-4 antibodies, such as nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab and ipilimumab), and other antibodies such as alemtuzumab, bevacizumab and gemtuzumab. In some embodiments, the combination therapy of the CCR8-specific antigen binding unit and anti-PD-1 as disclosed herein induces significant and / or synergistic tumor growth inhibition and survival benefits, as shown in Examples 27 and 28.
[0256] Furthermore, the methods herein contemplate therapeutic agents for immunomodulation, such as immunomodulators, immunosuppressants, tolerogens and immunostimulants. In addition, therapeutic agents acting on blood and hematopoietic organs, hematopoietic agents, growth factors, minerals and vitamins, anticoagulants, thrombolytics and antiplatelet drugs.
[0257] In order to treat renal cancer, the antigen binding unit of the present invention can be combined with sorafenib and / or Avastin. In order to treat endometrial diseases, the antigen binding unit of the present invention can be combined with doxorubicin, Taxotere (paclitaxel) and / or cisplatin (carboplatin). In order to treat ovarian cancer, the antigen binding unit of the present invention can be combined with cisplatin (carboplatin), Taxotere, doxorubicin, topotecan and / or tamoxifen. In order to treat breast cancer, the antigen binding unit of the present invention can be combined with Taxotere (paclitaxel), gemcitabine (capecitabine), tamoxifen, letrozole, Tarceva, Lapatinib, PD0325901, Avastin (avastin), Herceptin, OSI-906 and / or OSI-930. In order to treat lung cancer, the antigen binding unit of the present invention can be combined with Taxotere (paclitaxel), gemcitabine, cisplatin, pemetrexed, Tarceva, PD0325901 and / or Avastin.
[0258] Other therapeutic agents that can be combined with the antigen binding units of the present disclosure can be found in Goodman and Gilman's "The Pharmacological Basis of Therapeutics" Tenth Edition edited by Hardman, Limbird and Gilman, or the Physician's Desk Reference, both of which are incorporated herein by reference in their entirety.
[0259] Antigen binding units as described herein can be used in combination with reagents disclosed herein or other suitable reagents, depending on the conditions treated. Therefore, in some embodiments, one or more antigen binding units of the present disclosure will be co-administered with other reagents as described above. When used for combined therapy, antigen binding units as described herein are administered simultaneously or separately with a second agent. This combined administration can include administering two agents simultaneously with the same dosage form, administering agents simultaneously with different dosage forms, and administering alone. That is, antigen binding units as described herein and any of the above-mentioned agents can be prepared together with the same dosage form and administered simultaneously. Alternatively, antigen binding units of the present disclosure and any of the above-mentioned agents can be administered simultaneously, wherein the two agents exist as separate preparations. In another alternative, antigen binding units can be administered sequentially with any one or more of the above-mentioned agents, and vice versa. In some embodiments of the separate administration scheme, antigen binding units of the present disclosure and any of the above-mentioned agents are administered a few minutes, hours, or days apart.
[0260] The following examples section provides further description of the development and use of antigen binding units, polynucleotides, vectors and host cells.These examples are provided as a guide for those of ordinary skill in the art and are not intended to be limiting in any way. Example
[0261] The following examples are given for the purpose of illustrating various embodiments and are not meant to be limiting.
[0262] Example 1: Transient transfection of human CCR8 or cynomolgus monkey CCR8
[0263] Stable cell lines HEK293 and CHO-K1 overexpressing human CCR8, cynomolgus CCR8, or mouse CCR8 were produced by Genomeditech and used for immunization and antibody screening purposes. The lymphoma cell line HuT78 (TIB-161) expressing CCR8 was obtained from ATCC.
[0264] 24 hours before transfection, culture the cells to a density of approximately 5-8×10 6 cells / mL, and the survival rate was at least 95%. On the day of transfection, cells were plated at 2×10 6 Cells / ml were inoculated in ExpiCHO-S expression medium (50 mL) in a shake flask. 40 μL of plasmid DNA and 160 μL of EXPIFECTAMINE CHO reagent were incubated at room temperature, and the solution was slowly transferred to the shake flask, and the shake flask was gently rotated during the addition. The cells were incubated on an orbital shaker in a CO2 incubator at 37°C.
[0265] The 433H monoclonal antibody (BD Biosciences, #644092) that specifically binds to human CCR8 and 10A11-1 described in WO2020138489 were used as reference antibodies.
[0266] Example 2: Alignment of human, cynomolgus monkey and mouse CCR8 sequences
[0267] Human CCR8, cynomolgus monkey and mouse CCR8 sequences were retrieved from Uniprot and aligned ( Figure 1 ). While a two-sequence alignment of human and cynomolgus CCR8 yielded 94.37% sequence identity, the identity between mouse and human CCR8 (percent identity = 70.99%), as well as the identity between mouse and cynomolgus CCR8 (percent identity = 71.55%), significant differences were observed in the N-terminal extracellular domain (ECD) region and the C-terminal region. The sequence homology between the cynomolgus CCR8 ECD and the human CCR8 ECD is 68%, while the sequence homology between the mouse CCR8 ECD and the human CCR8 ECD is 52%. However, the acidic and tyrosine sulfated ECDs show negatively charged clusters, which have been successfully used to generate cross-reactive antibodies.
[0268] Example 3: Immunization and hybridoma
[0269] Balb / c and SJL mice were immunized to produce antibodies using gene gun method. Gene gun cassettes (Table 4-6) for gene immunization were prepared by mixing human CCR8 plasmid with other immune adjuvant plasmids (including mouse GM-CSF and mouse GM-FLT3L). In order to induce antibodies that cross-react with human and cynomolgus monkey CCR8, mice were immunized 5 times with human CCR8 plasmid, and then immunized with cynomolgus monkey CCR8 plasmid. Seven days after each immunization, serum titers of immunized mice were detected by FACS using human CCR8 overexpression cell lines. Three days before hybridoma fusion, mice with the best titer were selected for the final enhancement of HEK293-cynomolgus monkey CCR8 cell line.
[0270] Table 4: Plasmid ratios for cassette preparation
[0271]
[0272] Table 5: Immunization of mice using human CCR8 plasmid protocol
[0273]
[0274] Table 6: Immunization of mice using cynomolgus monkey CCR8 plasmid protocol
[0275]
[0276] Hybridoma fusion and subcloning
[0277] Mouse spleen cells isolated from high-titer Balb / c mice and myeloma fusion partners were fused by electric field-based electrofusion using the Cyto Pulse large chamber cell fusion electrotransformer (BTX, ECM2001). Single cell suspensions of spleen lymphocytes from immunized mice were fused with half the number of sp2 / 0-Ag14 (ATCC CRL1581) non-secreting mouse myeloma cells. The resulting cells were incubated at 2.0x10 4 Cells / well were seeded in 200ul selective DMEM medium in a flat-bottom 96-well cell culture plate, which contained high glucose (GIBICO, catalog number: 11995-065) and 20% FBS (GIBIO, catalog number 10091-148), and supplemented with 50X HAT (GIBISO, catalog number 21060-017). After 7 days of culture in a CO2 incubator, the medium containing HAT in the 96-well cell culture plate was replaced with a medium containing HT supplement (100X), liquid [GIBICO, catalog number: 11067030] and 10% FBS.
[0278] After 10 days, preliminary screening was performed by FACS. In this screening, 50 μl of supernatant was transferred from the fusion plate to a 96-well round bottom plate (Corning Incorporated, 3799) and mixed with a cynomolgus monkey CCR8 overexpression cell line. After incubation at 4 ° C for 1 hour, the cells were washed twice with FACS buffer (PBS containing 1.5% FBS) by centrifugation. The secondary antibody (AF647 labeled with goat anti-mouse IgG) was then added and incubated with the cells for 30 minutes at 4 ° C. After two additional washing steps, the cells were made into a cell suspension and read on a BD FACS Celesta reader.
[0279] Hybridoma cells from positive wells that have strong binding signals to CCR8 overexpressing cells in FACS screening are transferred to 24-well plates.After 3-5 days in culture, cell supernatants from individual wells are characterized by FACS and other functional assays.
[0280] Parental hybridoma cell lines that have been identified as positive antibodies are subcloned by limiting dilution. After 7 days of culture, positive monoclonal cell lines are screened by FACS. Monoclonal antibodies are generated from promising clones for further characterization. After ranking and validation by different assays, several hybridoma cells are selected for sequencing and further analysis.
[0281] Example 4: Screening of hybridoma clones by FACS binding and AF647-CCL1 binding blocking assay
[0282] Binding of hybridoma supernatants to CHO-K1-human CCR8 and ExpiCHO-S cynomolgus monkey CCR8 cells. A total of 660 96-well plates were inoculated and screened by FACS in combination with hybridomas derived from immunized animals. A total of 338 clones were identified as positive based on the geometric mean fluorescence intensity (MFI) multiple (MFI multiple = CCR8 positive cell MFI / CCR8 negative cell MFI)>5.
[0283] To obtain antibodies that cross-react with human and cynomolgus CCR8, hybridomas from mice immunized with human and cynomolgus CCR8 DNA were screened by FACS. Briefly, 50 μL of ExpiCHO-S cells (cell density: 2×10 6 Cells / mL, viability>90%) were incubated with an equal volume of hybridoma supernatant in a 96-well plate (Corning) at 4°C for 1 hour. After washing with FACS buffer (DPBS containing 2% FBS), the cells were incubated with secondary antibodies (Alexa Fluor 647-conjugated rabbit anti-mouse IgG, Jackson ImmunoResearch) cells / antibody mixtures were stained. Finally, the mixture was washed and resuspended with FACS buffer, and FACS analysis was performed on BD FACS Celesta. FlowJo software was used to analyze raw data. 13 hybridomas from immune mice showed strong binding to CHO-K1-human CCR8 and CHO-K1-cynomolgus monkey CCR8 cells (Table 7).
[0284] Blocking activity of hybridoma supernatants against CHO-K1-human CCR8 cells .
[0285] CHO-K1-human CCR8 cells were incubated with hybridoma supernatants and 4nM AF647-labeled human CCL1 at 4°C for 60 minutes. The cells were washed three times with FACS buffer (PBS buffer containing 2% FBS), and then the AF647 signal was detected by BD FACS Celesta equipment. Data were analyzed using Flowjo V10 software. Plots were drawn with binding inhibition rate relative to antibody concentration. 13 hybridomas from immunized mice showed significant blocking activity to CHO-K1-human CCR8 cells (Table 7).
[0286] Table 7: Hybridoma clone supernatants bind to CHO-K1-human CCR8, ExpiCHO-S cynomolgus monkey CCR8 cells, and block the binding of hCCL1 to HEK293-human CCR8 cells
[0287]
[0288] Example 5: Binding and blocking activity of purified mouse antibodies
[0289] The binding affinity of the purified antibodies was determined on human CCR8 and cynomolgus CCR8 overexpressing cells. Briefly, the assay used CFSE (Life technology, catalog number: C34554) labeled CHO-K1-human CCR8 cells mixed with CHO-K1 cells, CFSE labeled HEK293-human CCR8 cells mixed with HEK293 cells, or CFSE labeled HEK293-cynomolgus CCR8 mixed with HEK293 cells. The mixing ratio was 1:1. A total of 5×10 4Mixed cells were seeded in a 96-well plate and washed once with FACS buffer (DPBS containing 1% FBS). The cells were incubated with serially diluted purified hybridoma antibodies at 4°C for 1 hour. Antibodies were prepared in FACS buffer with 3-fold serial dilutions from 200nM to 0.003nM. After primary antibody incubation, the cells were washed three times with FACS buffer. Then, the cells were stained with a secondary antibody (AlexaFlu647-conjugated rabbit anti-mouse IgG, Jackson ImmunoResearch, #315606046) diluted 1:600 in FACS buffer and incubated at 4°C for 0.5 hours. After washing 3 times, the Alexa Fluor 647 signal of the stained cells was detected by BD FACS Celesta, and the MFI was determined. FlowJo software was used for analysis. The data were plotted as the logarithm of the antibody concentration relative to the mean fluorescence signal. EC was calculated using log(agonist) versus response variable slope (4 parameters) curve fitting in GraphPad Prism 8 (GraphPad Software). 50 Values. Twelve purified mouse antibodies, including 149F2C10, 153D4G2, 160D1E3, 164G10D6, 204A2G12, 206F1B2, 258H7F3, 262C2G7, 234G9C12, 191E12H8, 273H2G6, and 348E2D11, showed dose-dependent binding to CHO-K1 human CCR8 and HEK293-human CCR8 cells. These antibodies also cross-reacted with cynomolgus monkey CCR8 and showed dose-dependent binding to HEK293-cynomolgus monkey CCR8 cells. All antibodies did not bind to CHO-K1 and HEK293 cells. Except for 262C2G7 and 234G9C12, whose EC 50 In addition, the EC of the selected antibodies on human CCR8 50 Less than 5nM. EC of selected antibodies against cynomolgus monkey CCR8 50 Less than 1 nM, the EC of 348E2D11 50 Except (Table 8).
[0290] Table 8: Binding affinity of purified mouse antibodies to CHO-K1-human CCR8, HEK293-human CCR8 and HEK293-cynomolgus CCR8 cells.
[0291]
[0292] *not applicable
[0293] Blocking curves were generated to rank the CCL1 blocking activity of hybridoma antibodies. Briefly, a total of 5 × 10 4CHO-K1-human CCR8 cells or HEK293-human CCR8 cells were seeded in 96-well plates. The cells were incubated with serially diluted purified hybridoma antibodies and 4nM AF647-labeled human CCL1 (Almac, #CAF-07) at 4°C for 1 hour. Antibodies were prepared in FACS buffer with 3-fold serial dilutions from 200nM to 0.01nM. Then, the cells were washed three times with FACS buffer after culture. The Alexa Fluor 647 signal of the stained cells was detected by BD FACS Celesta, and the MFI was determined. FlowJo software was used for analysis. The data were plotted as the logarithm of the antibody concentration relative to the mean fluorescence signal. In GraphPad Prism 8 (GraphPad software), IC was determined using log (agonist) curve fitting relative to the response variable slope (4 parameters). 50 value.
[0294] As shown in Table 9, 12 purified mouse antibodies, including 149F2C10, 153D4G2, 160D1E3, 164G10D6, 204A2G12, 206F1B2, 258H7F3, 262C2G7, 234G9C12, 191E12H8, 273H2G6 and 348E2D11, can block the binding of CCL1.
[0295] Table 9: Activity of purified mouse antibodies in blocking human CCL1 binding to CHO-K1-human CCR8 and HEK293-human CCR8 cells.
[0296]
[0297] Example 6: Purified antibodies inhibit CCL1-induced β-arrestin recruitment
[0298] In response to stimulation, binding of ligands such as CCL1 to the CCR8 GPCR can activate G protein-independent signaling such as β-arrestin recruitment. This can lead to internalization of the chemokine receptor. The β-arrestin assay kit was purchased from Discover X. Briefly, CCR8 is fused in frame with a small enzyme donor fragment, ProLink (PK), and co-expressed in cells stably expressing a fusion protein of β-arrestin and a larger N-terminal deletion mutant of β-galactosidase (termed enzyme acceptor or EA). Activation of CCR8 stimulates β-arrestin binding to PK-tagged CCR8 and forces complementation of the two enzyme fragments to form active β-galactosidase. This interaction results in an increase in enzyme activity that can be measured using a chemiluminescent pathway hunter assay reagent. Briefly, in EC 80Cells were stimulated with CCL1 (CN-07, Almac) at 4 nM to activate β-arrestin recruitment, and the antibody of the present application or reference antibody 433H was added to assess its ability to block activated β-arrestin recruitment. Reference antibody 433H blocked β-arrestin recruitment, while purified antibodies 149F2C10, 153D4G2, 160D1E3, 164G10C6, 204A2G12 and 206F1B2 showed partial inhibition of β-arrestin recruitment (Table 10).
[0299] Table 10: Activity of purified antibodies in inhibiting CCL1-induced β-arrestin recruitment
[0300]
[0301] Example 7: Binding and blocking activity of antibodies that remove PTM sites
[0302] Antibody sequences generated using hybridoma technology are analyzed for post-translational modifications (PTMs), which can cause problems during the development of therapeutic proteins, such as increased heterogeneity, reduced bioactivity, reduced stability, immunogenicity, fragmentation, and aggregation. The potential impact of a PTM depends on its location and, in some cases, solvent exposure. The CDRs of all sequences were analyzed for asparagine deamination, aspartate isomerization, free cysteine thiol groups, N-glycosylation, oxidation, and fragmentation of potential hydrolysis sites.
[0303] For 149F2C10, there is Asn in the light chain CDR1 region 28 -Gly 29 (NG) deamidation site, which may cause stability issues. To reduce the risk of deamidation, new variants were designed to remove the NG site. The binding activity of the mutants with the NG site removed was tested on cells and the parent clone was used as a control.
[0304] The binding affinity of the antibodies with NG site removed was determined on human CCR8 and cynomolgus CCR8 overexpressing cells. Briefly, CFSE-labeled HEK293-human CCR8 cells or CFSE-labeled HEK293-cynomolgus CCR8 cells were mixed with HEK293 cells. The mixing ratio was 1:1. A total of 5x10 4Mixed cells were seeded in a 96-well plate and washed once with FACS buffer (DPBS containing 1% FBS). Cells were incubated with serially diluted purified hybridoma antibodies at 4°C for 1 hour. Antibodies were prepared in 3-fold serial dilutions from 100nM to 0.0017nM, or 25.3165nM to 0.0004nM in FACS buffer. 433H was used as a positive control. After primary antibody incubation, cells were washed three times with FACS buffer. Then, cells were stained with secondary antibodies (Alexa Fluor 647-conjugated rabbit anti-mouse IgG, Jackson ImmunoResearch, #315606046) diluted 1:600 in FACS buffer and incubated at 4°C for 0.5 hours. The Alexa Fluor 647 signal of the stained cells was detected by BD FACS Celesta, and the MFI was determined. FlowJo software was used for analysis. Data were plotted as the logarithm of the antibody concentration relative to the mean fluorescence signal. EC was calculated using log(agonist) versus response variable slope (4 parameters) curve fitting in GraphPad Prism 8 (GraphPad Software). 50 value.
[0305] Blocking curves were generated to rank the blocking activity of antibodies that remove PTM sites. Briefly, a total of 5 × 10 4 CHO-K1-human CCR8 cells were seeded in 96-well plates. The cells were incubated at 4°C for 1 hour with serially diluted purified hybridoma antibodies and 4nM Af647-labeled human CCL1 (Almac, #CAF-07). Antibodies were prepared in FACS buffer with 3-fold serial dilutions from 100nM to 0.0051nM. Then, the cells were washed three times with FACS buffer after incubation. The Alexa Fluor 647 signal of the stained cells was detected by BD FACSCelesta, and the MFI was determined. FlowJo software was used for analysis. The data were plotted as the logarithm of the antibody concentration relative to the mean fluorescence signal. In GraphPad Prism8 (GraphPad software), IC was determined using log (agonist) curve fitting relative to the response variable slope (4 parameters) 50 value.
[0306] As shown in Figure 2 and Table 11, 149F2C10_G29A showed the best binding activity to HEK293-human CCR8 and HEK293-cynomolgus monkey CCR8 among the antibodies with PTM sites removed, EC 500.129 nM and 0.173 nM, respectively. None of the antibodies showed nonspecific binding to HEK293 cells. As shown in Figure 3 and Table 11, 149F2C10_G29A showed the best blocking activity against CHO-K1-human CCR8 among the antibodies with PTM sites removed, IC 50 It is 0.725nM.
[0307] Table 11: Binding and blocking activities of antibodies with PTM sites removed on HEK293-human CCR8, HEK293-cynomolgus monkey CCR8 and CHO-K1-human CCR8 cells.
[0308]
[0309] 1 not applicable
[0310] Example 8: Humanization of anti-CCR8 antibodies
[0311] The humanization of the selected candidates 149F2C10_G29A (abbreviated as "149") and 348E2D11 (abbreviated as "348") was performed by transplanting the CDR residues of the mouse antibody onto the human germline framework. First, the sequences of the VH and VL regions of the selected candidates were compared with the human germline sequences, and the most suitable germline receptors were selected based on homology, typical structure and physical properties. Subsequently, the structural model of the candidate was generated using a homology model. The CDR regions in the heavy and light chains of the candidate antibodies were fixed, and the mouse framework was replaced by the selected human germline framework. Different residues between the mouse and human frameworks that may affect the CDR conformation or VH / VL interface were subjected to reverse mutations. DNA fragments encoding the designed humanized variants were synthesized and subcloned into an IgG expression vector. The DNA sequence was confirmed by sequencing. Different combinations of humanized heavy and light chains were co-transfected into CHO-K1 cells for expression. Finally, 9 humanized variants were derived from 149F2C10_G29A, including Hu149-1, Hu149-2, Hu149-3, Hu149-4, Hu149-5, Hu149-6, Hu149-7, Hu149-8 and Hu149-9. 9 humanized variants were derived from 348E2D11, including Hu348-1, Hu348-2, Hu348-3, Hu348-4, Hu348-5, Hu348-6, Hu348-7, Hu348-8 and Hu348-9. Using cells expressing the target antigen, humanized antibodies were compared with parent antibodies for antigen binding affinity by FACS.
[0312] Example 9: Binding and blocking activity of humanized 149
[0313] Place a total of 5 × 104 Cells were seeded in 96-well plates and washed once with FACS buffer (DPBD containing 1.5% FBS). Antibodies were prepared in 3-fold serial dilutions from 100nM to 0.0017nM in FACS buffer. Cells were incubated with 50μL of diluted antibodies at 4°C for 1 hour. The control group included cells incubated with human IgG1, 433H or mouse IgG2a. After primary antibody incubation, cells were washed 3 times with FACS buffer. Then, cells were stained at 4°C for 0.5 hours with Alexa Flu647-labeled anti-human IgG secondary antibodies (Jackson ImmunoResearch, #109606170) or Alexa Flu647-labeled anti-mouse IgG secondary antigens (Jackson ImmonoResearch, #115605072) in FACS buffer at a dilution of 1:600. After washing 3 times, flow cytometry was performed to measure binding.
[0314] The binding affinity of humanized 149 antibody was tested using HEK293-human CCR8 and HEK293-cynomolgus monkey CCR8 cells. The blocking activity of humanized 149 antibody was tested using CHO-K1-human CCR8 cells. As shown in Tables 12-13, Hu149-4 and Hu149-9 showed the best binding activity of humanized antibodies to HEK293-human CCR8 and HEK293-cynomolgus monkey CCR8 cells in two separate experimental settings. As shown in Tables 12-13, among the humanized antibodies, Hu149-4 and Hu149-9 showed the strongest blocking activity to CHO-K1-human CCR8 cells, IC 50 0.137nM and 0.119nM respectively.
[0315] Table 12: Binding and blocking activities of humanized 149 antibody on HEK293-human CCR8, HEK293-cynomolgus monkey CCR8 and CHO-K1-human CCR8 cells.
[0316]
[0317] 1 not applicable
[0318] Table 13: Binding and blocking activities of Hu149-9 antibody on HEK293-human CCR8, HEK293-cynomolgus monkey CCR8 and CHO-K1-human CCR8 cells.
[0319]
[0320] 1 not applicable
[0321] Example 10: Binding and blocking activity of humanized 348
[0322] The binding affinity of humanized 348 antibody was tested using HEK293-human CCR8 and ExpiCHO-S-cynomolgus monkey CCR8 cells. The blocking activity of humanized 348 antibody was tested using CHO-K1-human CCR8 cells. As shown in Table 14, Hu348-1, Hu348-2, Hu348-3, Hu348-4, Hu348-8, Hu348-9, parent antibody CM348 and 433H showed comparable binding affinity to HEK293-human CCR8, EC 50 They were 0.122nM, 0.119nM, 0.108nM, 0.109nM, 0.144nM, 0.182nM, 0.197nM and 0.091nM respectively. Interestingly, compared with EC 50 Compared with the parental antibody CM348 with an IC value of 0.087 nM, Hu348-4 showed a significant improvement in the optimal binding to ExpiCHO-S cynomolgus monkey CCR8 cells (Table 14). Hu348-4 and the parental antibody CM348 showed similar CCL1 binding blocking activity, IC 50 0.173 nM and 0.151 nM respectively (Table 14).
[0323] Table 14: Binding and blocking activities of humanized 348 antibody on HEK293-human CCR8, ExpiCHO-S-cynomolgus CCR8 and CHO-K1-human CCR8 cells.
[0324]
[0325]
[0326] 1 not applicable
[0327] Example 11: Selected humanized antibodies do not bind to human CCR1 or CCR4
[0328] CCR1 is a receptor for CC-type chemokines that binds to MIP-1-α, MIP-1-δ, RANTES, and MCP-3, and less efficiently to MIP-1-β or MCP-1, subsequently transducing signals by increasing intracellular calcium ion levels. CCR1 is responsible for stem cell proliferation.
[0329] CCR4 is a high-affinity receptor for CC-type chemokines CCL17 / TARC, CCL22 / MDC, and CKLF subtype 1 / CKLF1. The activity of this receptor is mediated by G(i) proteins that activate the phosphatidylinositol calcium second messenger system. It can act as a chemoattractant homing receptor on circulating memory lymphocytes and as a co-receptor for some primary HIV-2 isolates. In the central nervous system, CCR4 can mediate the survival of hippocampal neurons.
[0330] Human CCR8, CCR1 and CCR4 sequences were retrieved from Uniprot. The sequences were aligned to calculate sequence identity. While a two-sequence alignment of CCR1 and CCR8 yielded a sequence identity of 39.33%, the percentage between CCR4 and CCR8 was similar (percent identity = 43.13%). The sequence homology between CCR1 ECD and CCR8 ECD was 22.9%, while the sequence homology between CCR4 ECD and CCR8 ECD was 31.4%.
[0331] ExpiCHO-S cells were transiently transfected with human CCR1 or human CCR4. A total of 5 × 10 4 Cells were seeded in 96-well plates and washed once with FACS buffer (DPBS containing 1.5% FBS). Antibodies were prepared with 3-fold serial dilutions from 200nM to 0.00338nM in FACS buffer. Cells were incubated with 50 μL of diluted antibodies at 4 ° C for 1 hour. The control group included cells incubated with human IgG1, 433H or mouse IgG2a. After primary antibody incubation, cells were washed 3 times with FACS buffer. Then, Alexa Flu 647-labeled anti-human IgG secondary antibody (Jackson ImmunoResearch, #109606170) or Alexa Flu 647-labeled anti-mouse IgG secondary antibody (Jackson ImmonoResearch, #115605072) was diluted 1:600 in FACS buffer and stained for 0.5 hours at 4 ° C. Flow cytometry was performed to measure binding. As shown in Figure 4 and Table 15, the anti-CCR1 antibody (5F10B29) showed dose-dependent binding to ExpiCHO-CCR1 cells, and the EC 50 24.7 nM, while all selected humanized antibodies showed no or minimal binding to ExpiCHO-CCR1 cells; the anti-CCR4 antibody (1G1) showed a dose-dependent binding to ExpiCHO-CCR4 cells, with an EC 50 was 11.7 nM, while all selected humanized antibodies showed no or minimal binding to ExpiCHO-CCR 4 cells.
[0332] Table 15: Binding affinity of selected humanized antibodies to ExpiCHO-S-human CCR1 and ExpiCHO-S-human CCR4 cells.
[0333]
[0334] 1 Not applicable, 2 not completed
[0335] Example 12: Antibody-dependent cellular cytotoxicity (ADCC) function of selected humanized antibodies
[0336] The humanized antibodies were tested on CHO-K1 human CCR8 cells for human PBMC-based ADCC activity. The cryopreserved PBMCs (AllCells) of healthy subjects were thawed the day before the assay and cultured overnight in RPMI160 medium containing 10% FBS and 200IUIL-2 (R&D, catalog number: 202-IL) in a CO2 incubator. Target cells were labeled with CFSE (Life technology, catalog number: C34554) at a final concentration of 2.5 μM for 15 minutes. After staining, the cell concentration was adjusted to 6×10 4 cells / mL and mixed with 2 times the volume of PBMCs to adjust the volume to 1×10 6 Cells / mL (effector cell / target cell ratio is 40:1). Then, 150 μL of mixed target cell and effector cell suspensions are mixed with 50 μL of serially diluted antibodies in each well. Duplicate wells are prepared for each concentration of antibody. Target cells alone are used as a control group. After incubation for 5 hours at 37°C and 5% CO2, 1 μg / mL PI (Invitrogen, catalog number: 51-66211E) is added and analyzed by flow cytometry (BD FACSCelesta). Specific cytotoxicity is calculated by the following formula: Specific cytotoxicity = %PI-positive cells with antibody-%PI-positive cells without antibody.
[0337] Hu149-4 HuIgG1, Hu149-9 HuIgG1 and parent antibody CM149-HuIgG1 showed similar ADCC activity on CHO-K1 cells overexpressing human CCR8. Humanized Hu348-4 HuIgG1 and parent antibody CMP48 HuIgG1 showed similar ADCC activity on CHO-K1 cells overexpressing human CCR8 (Figure 5, Table 16).
[0338] Table 16: ADCC activity of humanized antibodies against CHO-K1-human CCR8 cell line
[0339] Antibody <![CDATA[EC 50 (nM)]]> Maximum specific lysis rate (%) CM149HuIgG1 0.0670 10.3 Hu149-4HuIgG1 0.00200 8.76 Hu149-9HuIgG1 0.0600 7.56 Human IgG1 NA 0.860 CM348HuIgG1 0.410 13.1 Hu348-4HuIgG1 0.517 13.5
[0340] 1 not applicable
[0341] Example 13: Selected humanized antibodies inhibit CCL1-induced β-arrestin recruitment
[0342] In the first experiment, CHO-K1 cells co-expressing human CCR8 labeled with ProLink (PK) and enzyme receptor (EA) were incubated with antibodies or CCL1 (CN-07, Almac) for 90 minutes before adding detection reagent (93-0001, DiscoveryX). CCL1 induced β-arrestin recruitment in a dose-dependent manner, and EC 50 The reference antibodies 433H, CM149 or Hu149-4 did not induce β-arrestin recruitment ( Figure 6 ).
[0343] In EC 80 CHO-K1 CCR8β-arrestin cells were stimulated with CCL1 (CN-07, Almac) at 4 nM to activate β-arrestin recruitment, and the selected humanized antibodies or reference antibodies were added to evaluate their ability to block activated β-arrestin recruitment. Because the subtype of the reference antibody 433H is mouse IgG2a, the subtype of all tested antibodies was changed to mouse IgG2b. As shown in Table 17, Hu149-9 and Hu10A11-1 showed similar inhibitory activity on β-arrestin recruitment, IC 50 433H showed better inhibitory activity against β-arrestin recruitment than Hu149-9, with an IC 50 0.23nM and 8.64nM respectively.
[0344] Table 17: Selected humanized antibodies inhibit CCL1-induced β-arrestin recruitment in CHO-K1-human CCR8 β-arrestin cells
[0345]
[0346] 1 not applicable
[0347] Example 14: Humanized antibodies inhibit CCL1-induced cell migration
[0348] The activity of humanized anti-CCR8 antibodies in blocking CCL1-induced cell migration was evaluated. CHO-K1-human CCR8 cells with or without anti-CCR8 antibodies were added to the upper chamber of the Transwell-96 permeable support. The chemoattractant CCL1 was added to the lower chamber. The cells passed through the membrane from the top and adhered to the back of the membrane. The cells were detached from the membrane using trypsin and quantified by Cell Titer Glo. Figure 7 As shown, Hu149-4-mIgG2a, Hu149-9-mIgG2a, and reference antibody 433H were tested in a migration assay. Hu149-4-mIgG2a, Hu149-9-mIgG2a, and 433H blocked CCL1-induced cell migration. 50 2.95nM, 1.92nM and 1.25nM respectively ( Figure 7 , Table 18).
[0349] Inhibition rate (%) = (1-(chemotaxis index (sample)-1 / chemotaxis (no antibody)-1)) x 100
[0350] Chemotaxis index = CTG value (sample) / CTG value (without CCL1)
[0351] Table 18: Activity of anti-CCR8 antibodies in blocking CCL1-induced cell migration
[0352] Antibody <![CDATA[IC 50 (nM)]]> Maximum inhibition rate (%) Hu149-4-mIgG2a 2.95 91.5 Hu149-9-mIgG2a 1.92 102 433H 1.25 117
[0353] Example 15: Affinity Maturation of Exemplary Anti-CCR8 Antibody HU149-9
[0354] To improve the binding affinity of humanized variant 149-9 to human CCR8, affinity maturation was performed using phage display technology. The parent antibody sequence was used as a template, assembled in a VH-VL format with a (G4S)3 linker in the middle, and cloned into the pComb3XSS phage vector.
[0355] The phage vector containing scFv was transformed into TG1, and antigen binding of 149-9scFv displayed by phage was verified by FACS. Two CDR mutagenesis libraries targeting CDRH3 and CDRL3 were constructed by soft mutagenesis-guided primer design and overlapping PCR, respectively. CDR positions were defined by the Kabat numbering system. Amino acid residues within the CDR3 loop were randomized using NNK coding. The mutation rate at each position was kept at approximately 50% to maximize retention of the original binding epitope. Harsh and mild washing conditions were added to reduce nonspecific binders and wild-type occupancy during affinity-driven cell-based panning separation.
[0356] Example 16: Screening of affinity matured variants by FACS binding
[0357] 50-100 random clones from each library were sequenced and sequence alignment with the wild-type sequence was used to assess the quality of the mutant library, including mutation position and mutation rate. Up to 5500 single clones were selected for periplasmic extract (PPE) preparation and FACS binding screening ( Fig. 8A -B). Clones with high signal / background ratios were sequenced, 14 scFvs were purified, then combined by FACS, and then confirmed by human IgG1 conversion (combinations of beneficial mutations from heavy and light chains). After transient expression in HEK293 cells, IgG in the culture supernatant was purified by one-step protein A. Purified IgG was further characterized by SDS-PAGE purification, SEC-HPLC aggregation, and UV280 concentration. Antigen binding was verified by FACS (Tables 19-20). In view of the fact that the ADCC effect may greatly promote Treg depletion, Fc mutations including S239D / I332E (US2005054832A1) and L235V / F243L / R292P / Y300L / P396L (AU2004204494B2) were introduced.
[0358] Table 19: FACS binding data of purified scFv to CHO-K1-human CCR8 cells
[0359]
[0360] Table 20: IgG production of 149 affinity matured variants
[0361] HCDR3 LCDR3 149-11 VH-PH5-P7B9 wild type 149-12 VH-PH5-P9E9 wild type 149-13 VH-PH5-P5F7 wild type 149-14 VH-PH5-P3E3 wild type 149-15 VH-PH7-P2H12(S41P) wild type 149-16 wild type VH-PH5-P2B6(LCDR3) 149-17 wild type VL-PH5-P5D9 149-18 wild type VL-PH5-P3E4 149-19 VH-PH5-P7B9 VH-PH5-P2B6(LCDR3) 149-20 VH-PH5-P9E9 VH-PH5-P2B6(LCDR3) 149-21 VH-PH5-P5F7 VH-PH5-P2B6(LCDR3) 149-22 VH-PH5-P3E3 VH-PH5-P2B6(LCDR3) 149-23 VH-PH5-P7B9(S41P) VH-PH5-P2B6(LCDR3) 149-24 VH-PH5-P9E9(S41P) VH-PH5-P2B6(LCDR3)
[0362] Example 17: Binding and blocking activity of selected affinity matured antibodies
[0363] Using CHO-K1-human CCR8 and HEK293-cynomolgus monkey CCR8 cells, the binding affinity of affinity-matured antibody Hu149 was compared with that of the parent antibody by FACS analysis (Sartourius, iQue3). The blocking activity of affinity-matured antibody Hu149 was evaluated on the CHO-K1-human CCR8 cell line. As shown in Table 21, except Hu149-21, all tested affinity-matured antibodies showed similar binding affinity and blocking activity to CHO-K1-human CCR8 and HEK293 cynomolgus monkey CCR8 cells.
[0364] Table 21: Activity of affinity matured antibodies on CHO-K1 -human CCR8 and HEK293 -cynomolgus CCR8 cells.
[0365]
[0366] 1 not applicable
[0367] HuT78 cells expressing endogenous human CCR8 were used to determine the binding affinity of selected affinity-matured anti-CCR8 antibodies. Briefly, a total of 5 × 10 4 Cells were seeded in 96-well plates and washed once with FACS buffer (DPBS containing 1.5% FBS). Antibodies were prepared in FACS buffer with 4-fold serial dilutions from 200nM to 0.0122nM. Cells were incubated with 50 μL of diluted antibodies at 4 ° C for 1 hour. After primary antibody incubation, cells were washed 3 times with FACS buffer. Then, Alexa Flu 647-labeled anti-human IgG secondary antibodies (Jackson ImmunoResearch, #109606170) were diluted 1:600 in FACS buffer and stained for 0.5 hours at 4 ° C. After washing 3 times, flow cytometry (Sartourius, iQue3) was performed to measure the binding affinity of the antibodies.
[0368] As shown in Table 22, Hu149-11, Hu149-12, and Hu149-14 showed improved binding to HuT78 cells compared to the parent antibody Hu149-9. The EC values of Hu149-11, Hu149-12, and Hu149-14 were 50 The maximum MFI values of Hu149-16, Hu149-18, Hu149-19, Hu149-20, Hu149-21, Hu149-22, Hu149-23 and Hu149-24 were significantly higher than those of Hu149-9. Whether it is due to nonspecific binding needs further investigation.
[0369] Table 22: Binding activity of affinity matured antibodies to HuT78 cells.
[0370]
[0371] Example 18: Binding of selected affinity matured antibodies to human PBMCs
[0372] CCR8 is highly expressed in tumor-infiltrating regulatory T cells, but not in healthy T cells or effector T cells, so PBMCs from healthy individuals can be used to detect nonspecific binding of CCR8 antibodies. Briefly, PBMCs were thawed and then blocked with Fc blocker for 10 minutes at 4°C, incubated with 200 nM antibody and PBMCs for 1 hour at 4°C, and stained with FITC-anti-CD3, BV421-anti-CD4, and AF647-anti-human Fc for 30 minutes at 4°C. The stained cells were analyzed by flow cytometry. Tables 23-24 show that Hu149-11 had no or only a small amount of binding to CD4+T and CD4-T cells, while Hu149-18, Hu149-19, Hu149-20, Hu149-21, Hu149-22, Hu149-23 and Hu149-24 had significant binding to CD4+T and CD4-T cells compared to the hIgG1 isotype control group. Based on FACS staining and gating strategy, CD4-T cells were considered to be CD8+T cells.
[0373] Table 23: Flow cytometry analysis of Hu149-11 and Hu149-18 to Hu149-24 binding to CD4+ T cells
[0374] cell Antibody MFI BV421+,CD4+ hIgG1 isotype, 200 nM 15.6 BV421+,CD4+ Hu149-24,200nM 2157 BV421+,CD4+ Hu149-23,200nM 144 BV421+,CD4+ Hu149-22,200nM 283 BV421+,CD4+ Hu149-21,200nM 120 BV421+,CD4+ Hu149-20,200nM 2352 BV421+,CD4+ Hu149-19,200nM 184 BV421+,CD4+ Hu149-18,200nM 933 BV421+,CD4+ Hu149-11,200nM 23.1 BV421+,CD4+ Hu433H, 200nM 17.5
[0375] Table 24: Flow cytometry analysis of Hu149-11 and Hu149-18 to Hu149-24 binding to CD4-T cells
[0376] cell Antibody MFI BV421-,CD4- hIgG1 isotype, 200 nM 33.9 BV421-,CD4- Hu149-24,200nM 3819 BV421-,CD4- Hu149-23,200nM 693 BV421-,CD4- Hu149-22,200nM 1328 BV421-,CD4- Hu149-21,200nM 757 BV421-,CD4- Hu149-20,200nM 4512 BV421-,CD4- Hu149-19,200nM 999 BV421-,CD4- Hu149-18,200nM 2751 BV421-,CD4- Hu149-11,200nM 83.9 BV421-,CD4- Hu433H, 200nM 45.2
[0377] Example 19: Affinity matured antibodies inhibit CCL1-induced β-arrestin recruitment
[0378] In EC 80 CHO-K1 CCR8β-arrestin cells were stimulated with CCL1 (CN-07, Almac) at 4 nM to activate β-arrestin recruitment, and the selected humanized antibodies or reference antibodies were added to evaluate their ability to block activated β-arrestin recruitment. As shown in Figure 9 and Table 25, Hu149-11, Hu149-12, Hu149-18 and 433H showed similar inhibitory activity on β-arrestin recruitment, IC 50 They are 0.800nM, 0.350nM, 0.610nM and 0.890nM respectively.
[0379] Table 25: Activity of mature antibodies in inhibiting CCL1 induced β-arrestin recruitment.
[0380]
[0381] The term "NA" means "not applicable".
[0382] Example 20: Affinity matured antibodies inhibit CCL1-induced cell migration
[0383] The activity of mature anti-CCR8 antibodies in blocking CCL1-induced cell migration was evaluated. CHO-K1-human CCR8 cells with or without anti-CCR8 antibodies were added to the upper chamber of the Transwell 96 permeable support. The chemoattractant CCL1 was added to the lower chamber. The cells passed through the membrane from the top and adhered to the back of the membrane. The cells were detached from the membrane using trypsin and quantified by Cell Titer Glo.
[0384] Inhibition rate (%) = (1-(chemotaxis index (sample)-1 / chemotaxis (no antibody)-1)) x 100
[0385] Chemotaxis index = CTG value (sample) / CTG value (no CCL1)
[0386] like Fig.10 As shown, Hu149-11G1, Hu149-12G1, and Hu348-4m2G1 were tested in the migration assay; 433H was used as a positive control. Hu149-11G1, Hu149-12G1, and Hu348-4m2G1 blocked CCL1-induced cell migration. 50 They were 0.849 nM, 0.953 nM and 1.42 nM respectively (Table 26).
[0387] Table 26: Activity of anti-CCR8 antibodies in blocking CCL1-induced cell migration
[0388] Antibody <![CDATA[IC 50 (nM)]]> Maximum inhibition rate (%) Hu149-11G1 0.849 105 Hu149-12G1 0.953 104 Hu348-4m2G1 1.42 81.5 Hu10A11-1 1.47 101 433H 0.278 104
[0389] Example 21: Binding and blocking activity of FC variants of humanized anti-CCR8 antibodies
[0390] The binding and blocking activities of humanized anti-CCR8 antibodies with different Fc variants were evaluated on the CHO-K1-human CCR8 cell line, and their cross-reactions on the above-mentioned HEK293-cynomolgus monkey CCR8 cell line were evaluated. As shown in Table 27, Hu149-11G1m and Hu149-11G1x exhibited similar binding and blocking affinities as their parent antibody Hu149-11G1. In addition, Hu348-4-m2G1m and Hu348-4-m2G1x also exhibited similar binding and blocking activities as their parent antibody Hu348-4-m2G1. Compared with Hu10A11-1 as its parent antibody, Hu149-11G1m, Hu149-11G1x, Hu348-4-m2G1m and Hu348-4-m2G1x also showed better binding activity to CHO-cynomolgus monkey CCR8 cells. As shown in Figure 11 and Table 28, Hu149-11G1m and Hu149-11G1x also showed better binding activity and higher binding signal to HuT78 cells compared to Hu10A11-1. Hu348-4-m2G1m and Hu348-4-m2G1x also showed better binding activity to HuT78 cells compared to Hu10A11-1.
[0391] Table 27: Activity of humanized anti-CCR8 antibody Fc variants on CHO-K1-human CCR8 and HEK293-cynomolgus monkey CCR8 cells
[0392]
[0393] Table 28: Activity of Fc variants of humanized anti-CCR8 antibodies on HuT78 cells
[0394]
[0395] Example 22: ADCC activity of FC variants of humanized anti-CCR8 antibodies
[0396] Human FcγRIIIa exhibits dimorphism at position 158. One allele (V158) encodes a higher Fc affinity receptor variant with valine at amino acid residue 158, and the other (F158) encodes a lower Fc affinity receptor variant with phenylalanine at amino acid residue 158. Jurkat T cells expressing the firefly luciferase gene under the control of NFAT response elements and low affinity FcγRIIIa variants (F158, catalog number: 60540), and Jurkat T cells expressing the firefly luciferase gene under the control of NFAT response elements and high affinity FcβRIIIa mutants (V158, catalog number: 60541) were purchased from BPS biosciences.
[0397] On the day before the assay, CD16a / NFAT-Jurkat cells (BPS 60640 or 60541) were seeded in assay medium and grown for 1 day. On the day of the assay, 1 x 10 4 Target cells were seeded in a white opaque 96-well plate. Anti-CCR8 human IgG1 or control antibody was added, mixed and incubated for 1 hour at 37°C and 5% CO2. CD16a / NFAT reporter Jurkat cells were collected by centrifugation and resuspended in assay medium. 6 x 10 4 cells / well and incubated with anti-CCR8 or nonspecific negative control antibody. 100 μL of assay medium was added to the cell-free control wells (for determination of background luminescence). The culture plates were incubated in a CO2 incubator at 37°C for 5 hours. After 5 hours of incubation, 50 μl of one-step luciferase reagent was added to each well and gently shaken at room temperature for 30 minutes. Luminescence was measured using a luminometer. Data analysis: The average background luminescence (cell-free control wells) was subtracted from the luminescence readings of all wells. Nonlinear regression analysis was performed by GraphPadPrism 8 (GraphPad Software) and EC was calculated. 50 value.
[0398] As shown in Figures 12-13 and Table 29, Hu149-11G1 (wild-type variant) and Hu10A11-1 (wild-type variant) showed ADCC activity similar to that of V or F variant CD16a / NFAT-Jurkat cells on CHO-human CCR8 cells expressing high levels of CCR8. However, the potency of Hu149-11G1 (wild-type variant) was 2.5-5.5 times that of Hu10A11-1 (wild-type mutant) because HuT78 cells were used as target cells, which endogenously express CCR8 and have a lower expression level of CCR8 than CHO-CCR8. The EC of Hu149-11G1 (wild-type variant) and Hu10A11-1 (wild-type mutant) with V variant CD16a / NFAT-Jurkat cells on HuT78 cells was 2.5-5.5 times that of Hu10A11-1 (wild-type mutant). 50 EC of Hu149-11G1 (wild-type variant) and Hu10A11-1 (wild-type variant) on Hut78 with F variant CD16a / NFAT-Jurkat cells 500.402 nM, 2.20 nM respectively (Figures 14-15 and Table 29). As shown in Figures 12-15 and Table 29, the ADCC activity of Hu149-11G1m (ADCC enhancing variant with L235V / F243L / R292P / Y300L / P396LFc mutations) is much better than that of Hu149-11G1.
[0399] Table 29: ADCC activity of affinity matured antibodies with CD16a / NFAT-Jurkat reporter cells on CHO-K1-human CCR8 and HuT78 cells.
[0400]
[0401] 1 not applicable
[0402] The humanized antibodies were tested on CHO-K1 human CCR8 cells for human PBMC-based ADCC activity. The day before the assay, cryopreserved PBMCs (AllCells) from healthy subjects were thawed and cultured overnight in a CO2 incubator in RPMI1640 medium containing 10% FBS and 200 IU IL-2 (R&D, catalog number: 202-IL). Target cells were labeled with CFSE (Lifetechnology, catalog number: C34554) at a final concentration of 2.5 μM for 15 minutes. After staining, the cell concentration was adjusted to 6×10 4 cells / mL and mixed with 2 times the volume of PBMCs to adjust the volume to 1×10 6 Cells / mL (effector cell / target cell ratio is 40:1). Then, 150 μL of mixed target cell and effector cell suspensions are mixed with 50 μL of serially diluted antibodies in each well. Duplicate wells are prepared for each concentration of antibody. Target cells alone are used as a control group. After incubation for 5 hours at 37°C and 5% CO2, 1 μg / mL PI (Invitrogen, catalog number: 51-66211E) is added and analyzed by flow cytometry (BD FACS Celesta). Specific cytotoxicity is calculated by the following formula: Specific cytotoxicity = %PI-positive cells with antibody - %PI-positive cells without antibody.
[0403] As shown in Figure 16 and Table 30, Hu-149-11G1 (wild-type variant) was more effective than 10A11-1 (wild-type variant) in ADCC, with an EC 50Compared with Hu149-11G1, Hu149-11G1m (ADCC-enhanced variant with L235V / F243L / R292P / Y300L / P396L Fc mutations) showed significantly improved ADCC activity against CHO-K1-human CCR8 cells, EC 50 0.0000850nM and 0.0139nM respectively.
[0404] Table 30: ADCC activity of antibodies with affinity maturation of PBMCs on CHO-K1-human CCR8 cells
[0405] Antibody <![CDATA[EC 50 (nM)]]> Maximum specific lysis rate (%) Hu433H 0.00395 37.3 Hu10A11-1 0.0261 34.0 Hu149-11G1 0.0139 52.5 Hu149-11G1m 0.0000850 46.6 Hu149-11G1x 0.000384 44.2 Hu149-12G1 0.0113 36.4 Hu149-12G1m 0.000136 44.2 Hu149-12G1x 0.000828 53.0 Hu348-4-m2G1 0.00483 41.1 Hu348-4-m2G1m 0.000608 50.7 Hu348-4-m2G1x 0.000516 40.5 HuIgG1 <![CDATA[NA 1 ]]> -1.90
[0406] 1 not applicable
[0407] Example 23: FC variant of humanized anti-CCR8 antibody inhibits CCL1-induced β-arrestin recruitment
[0408] In EC 80 CHO-K1 CCR8β-arrestin cells were stimulated with CCL1 (CN-07, Almac) at 4 nM to activate β-arrestin recruitment, and selected humanized antibodies and reference antibodies were added to evaluate their ability to block activated β-arrestin recruitment. As shown in Figure 17 and Table 31, Hu149-11G1m inhibited β-arrestin recruitment more effectively than Hu10A11-1, IC 50 The inhibitory activity of Hu149-11G1m and Hu149-12G1m was similar to that of Hu149-11G1m, with IC values of 2.09 nM and 37.1 nM, respectively, and the maximum inhibition rates were 72.7% and 43.6%, respectively. 50 2.09nM and 1.16nM respectively.
[0409] Table 31: Activity of affinity matured antibodies in inhibiting CCL1-induced β-arrestin recruitment
[0410]
[0411] 1 not applicable
[0412] Example 24: Binding of FC variants of humanized anti-CCR8 antibodies to human peripheral blood mononuclear cells (PBMCs)
[0413] PBMCs of healthy people were used to detect nonspecific binding of Fc variants of humanized anti-CCR8 antibodies. Briefly, PBMCs were thawed and then blocked with Fc blockers for 10 minutes at 4°C, incubated with 200nM antibodies and PBMCs for 1 hour at 4°C, and stained with FITC-anti-CD3, BV421-anti-CD4, and AF647-anti-human Fc for 30 minutes at 4°C. The stained cells were analyzed by flow cytometry. As shown in Table 32, the Fc variants of Hu149-11 and Hu149-12 showed no or minimal binding to CD4+T and CD4-T cells. Hu348-4-m2G1m showed significant binding to CD4+T and CD4-T cells.
[0414] Table 32: Flow cytometric analysis of binding of Fc variants of humanized anti-CCR8 antibodies to human CD4+ T cells
[0415] cell Antibody MFI CD3+,CD4+ hIgG 1 isoform, 200 nM 41.0 CD3+,CD4+ Hu348-4-m2G 1x, 200nM 78.1 CD3+,CD4+ Hu348-4-m2G 1m,200nM 1645.0 CD3+,CD4+ Hu348-4-m2G 1,200nM 77.5 CD3+,CD4+ Hu149-12G1x, 200nM 59.7 CD3+,CD4+ Hu10A11-1,200nM 35.3 CD3+,CD4+ Hu433H, 200nM 16.0 CD3+,CD4+ Hu149-12G1m, 200nM 44.8 CD3+,CD4+ Hu149-12G1, 200nM 31.5 CD3+,CD4+ Hu149-11G1x, 200nM 64.6 CD3+,CD4+ Hu149-11G1m, 200nM 38.2 CD3+,CD4+ Hu149-11G1,200nM 34.5 CD3+,CD4+ Hu10A11-1,200nM 44.5 CD3+,CD4+ Hu433H, 200nM 14.3
[0416] Example 25: Expression of CCR8 in different immune cell populations
[0417] Frozen human free tumor cells (hDTCs) from patients with renal cancer, bladder cancer, breast cancer, colorectal cancer, and melanoma were purchased from Discovery Life Sciences. Cells were thawed according to the supplier's instructions and filtered through a 70 μm cell strainer. Cells were then counted and analyzed with Zombie Violet at room temperature. TM Fixable viability dye (Biolegend, catalog number: 423114, 1: 1000 in PBS) staining for 15 minutes. Wash cells with FACS staining buffer (Biolegend, catalog number: 420201) and inoculate 100 μl of 1-2 million cells / well hDTC in each well of a 96-well plate. hDTCs were first pre-stained with human TruStain FcX (BioLegend, catalog number: 422302). The cells were then surface stained and intracellularly stained using a eukaryotic transcription factor staining buffer kit (Biolegend, catalog number: 424401) according to the manufacturer's protocol. Each hDTC sample contains an FMO control to ensure accurate gating. Samples were collected using a BD LSRFortessa X-20 and analyzed using FlowJo (BD Biosciences). A complete list of antibodies detected by flow cytometry is shown in Table 33.
[0418] Table 33: Complete list of antibodies for flow cytometric detection of hDTC immunophenotyping
[0419] Target Fluorophore Number of clones Product Number Manufacturer EpCAM+ FITC 9C4 324204 Biolegend CD45+ BUV737 HI30 748719 BD biosciences CD19+ BV650 HIB19 302238 Biolegend CD3+ PerCP-Cy5.5 SK7 344808 Biolegend CD4+ BUV395 SK3 563550 BD biosciences CD8+ BV711 RPA-T8 563676 BD biosciences CD56+ APC HCD56 318310 Biolegend CD11b+ PE-CF594 ICRF44 562399 BD biosciences CD25+ PE-Cy7 2A3 335789 BD biosciences CCR8+ BV605 433H 747577 BD biosciences Foxp3+ PE 206D 320108 Biolegend
[0420] Flow cytometry was used to evaluate the expression pattern of CCR8 protein in different immune cell populations. Experiments were performed in hDTCs and donor-matched PBMCs. CCR8 could not be detected on the surface of major immune cell populations of PBMCs, including FoxP3+Treg cells, CD8+T cells, CD11b+ myeloid cells, B cells, and NK cells. Fig.18 In contrast, high CCR8 expression was detected in the FoxP3+ Treg population of donor-matched hDTCs ( Fig.19 ). CCR8 was mildly induced in CD8 T cells of hDTCs and was not detected in other populations, including CD11b+ myeloid cells, B cells, and NK cells. CCR8 was also not detected in FoxP3- conventional CD4+ T cells in peripheral blood or hDTCs. These data suggest that CCR8 is only upregulated in Tregs in the tumor microenvironment, likely due to TCR-mediated Treg activation. By examining the expression of CCR8 in hDTCs of different cancer types, two subpopulations of CCR8+ Tregs were observed: CCR8-lo (subpopulation 1) and CCR8-hi (subpopulation 2) populations. Within the same cancer type, Tregs from different donors exhibited heterogeneity: some donors had only subpopulation 1 ( Fig. 20 Figures E, G, H, L, N) or subgroups 1 and 2 ( Fig. 20 ( Figures A, B, C, D, F, I, J, K, M ). It has been reported that CCR8 expression is positively correlated with several activation markers and immune checkpoint molecules, such as Lag3, Klrg1, Tnfrsf4, Tnfrssf9 and Il2ra, Helios, the costimulatory molecule Cd81, and the secreted molecules Areg and Il10 (1), suggesting that CCR8-hi Treg (subset 2) may have a highly suppressive phenotype.
[0421] Example 26: CCR8 antibody treatment significantly reduces tumor volume
[0422] Female transgenic mice aged 6-8 weeks that had been engineered to express the human CCR8 gene instead of mouse CCR8 were purchased from Bioytogen (Wakefield, MA) and acclimated for one week before the start of the study. Mouse colorectal cancer cell line MC38 was cultured at 0.5 × 10 6 Cells / 100 μl / mouse were implanted subcutaneously into the right flank of mice. Prior to inoculation, cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) for no more than three generations. Cells were grown at 37°C in a humidified atmosphere containing 5% CO2. After reaching 80-85% confluence, cells were harvested and cultured at 5x10 per ml. 6The cells were resuspended in a 1:1 mixture of serum-free RPMI 1640 and Matrigel.
[0423] Mice were monitored for tumor growth twice a week after cell implantation. For tumor measurement, the length and width of each tumor were measured using calipers, and the volume was calculated according to the following formula: Tumor volume (mm 3 )=(width(mm)xlength(mm) 2 ) / 2. On the day of treatment initiation, all tumors were measured, outliers excluded, and mice were randomly assigned to treatment groups. For anti-CCR8 treatment, a human IgG1 antibody was developed and engineered (for enhanced ADCC activity) with an engineered human IgG1 Fc. As a control, mice were administered a nonspecific human IgG1 antibody with the same Fc mutations as the experimental antibody. Treatment drugs were given by intraperitoneal injection (ip) starting 7 days after tumor inoculation on study day 0, when the mean tumor volume in each group was approximately 120 mm 3 Subsequent treatments were given on study days 3, 7, and 11.
[0424] Continue to measure tumors at least twice a week until tumor volume exceeds 10% of the animal weight, or approximately 2000 mm. 3 The changes in tumor size are shown by plotting individual tumor volumes for each treatment group on day 15 after the animals were first treated with Hu149-11G1m ( Fig.21 ). Hu149-11G1m treatment significantly reduced tumor growth compared to control IgG1 when the treatment dose was 3 or 10 mg / kg (p<0.05). No significant mean tumor growth inhibition was observed with Hu149-11G1m when administered at 1, 0.3 or 0.1 mg / kg. P values were calculated using unpaired two-tailed t-test analysis of calculated tumor volumes at the end of the study (day 15). See Fig.21 , where statistical significance was determined by unpaired two-tailed t-test comparing Hu149-11G1m to human IgG1 control, *p<0.05, **p<0.01, and ns p>0.05.
[0425] Example 27: Anti-tumor efficacy of CCR8 antibody combined with anti-PD-1 antibody in HCCR8 knock-in transgenic mouse MC38 tumor model
[0426] This study tested the anti-tumor efficacy of CCR8 antibodies as a single agent and in combination with PD-1 antibodies in vivo. More specifically, the efficacy of Hu149-11G1m in human CCR8 transgenic mice carrying MC38 tumors was tested. MC38 is a mouse colon cancer cell line. Mice were inoculated subcutaneously with MC38, and then Hu149-11G1m was administered to tumor-bearing mice at a dose of 3 mg / kg twice a week as a single agent or in combination with an anti-PD-1 antibody (Biocell cat#CP151) at a dose of 5 mg / kg. Tumor growth was monitored throughout the study, and survival was recorded at the end of the study. Mice that achieved complete tumor regression were re-excited with tumors to test the sustainability of the anti-tumor effect. As described below, in the combined treatment group, a higher survival rate was obtained and significant depletion of Treg was observed.
[0427] MC38 mouse colon cancer cells were cultured in DMEM medium supplemented with 10% FBS and 1x penicillin / streptomycin. After several in vitro passages, tumor cells were collected using TrypLE Express reagent, counted, and diluted to 10E06 cells / mL in PBS. An equal volume of Matrigel was added to the cell solution to a final concentration of 5E06 cells / mL.
[0428] Transgenic mice with human genes were used in this study. Based on the C57Bl / 6 mouse strain, these animals have the human CCR8 gene inserted into the mouse CCR8 locus. Transgenic hCCR8 mice were inoculated by injecting 100 μL of cell suspension into their right hind flank. After 7 days of observation, the tumor volume of the mice was measured and 10 animals were divided into 4 treatment groups. The average tumor volume in each group was approximately 100 mm 3 Tumor-bearing mice were injected twice weekly with Hu149-11G1m 3 mpk alone or in combination with anti-PD-1. Human IgG1 with matched Fc was used as negative control (hIgG1 control). Tumor volume (TV) was assessed twice weekly using the formula TV = 0.5 x L x W x W until the tumor volume approached 1500 mm 3 , and then the mice were humanely euthanized.
[0429] On day 105, 17 tumor-eradicated mice were re-challenged with 5E05 MC38 tumor cells, including 10 mice from the combination treatment group and 7 mice from the anti-PD-1 treatment group. Tumor growth was monitored until day 131. All mice remained tumor-free.
[0430] The results showed that MC38 tumors harvested from inoculated C57Bl / 6 transgenic mice did express human CCR8 on their Tregs. Fig. 22As shown, treatment with 3 mg / kg of Hu149-11G1m showed a moderate anti-tumor response, which was similar to the effect of anti-PD-1 antibodies. Combination treatment of 3 mg / kg of Hu149-11G1m with 5 mg / kg of anti-PD-1 further reduced the average tumor volume, and this anti-tumor effect persisted after stopping drug treatment. Mice with complete tumor regression did not have any tumor growth 15 weeks after tumor re-challenge ( Fig. 22 ).like Fig.23 As shown, the combined treatment group showed a higher survival rate. Importantly, the results also showed that there was no substantial average weight loss in any group using Hu149-11G1m alone or in combination with anti-PD-1 antibodies. In summary, these data indicate that CCR8 antibodies (such as Hu149-11G1m) can mediate anti-tumor activity in vivo and further provide sensitivity to anti-PD-1 antibodies. The anti-tumor effect is sustainable.
[0431] Example 28: Antitumor activity of CCR8 antibody combined with anti-PD-1 antibody in CCR8 knock-in transgenic mice inoculated with E0771 tumors
[0432] In this study, immunocompetent mice engineered with human CCR8 gene instead of mouse gene were inoculated with mouse E0771 breast cancer cells. Tumor-bearing mice were treated with Hu149-11G1m alone or in combination with anti-PD-1 antibody (Biocell cat#CP151) and tumor growth was assessed.
[0433] Transgenic mice with human gene knock-in were used in this study. Based on the C57Bl / 6 mouse strain, these animals have the human CCR8 gene inserted into the locus of mouse CCR8. The E0771 cell line is a medullary breast cancer that develops spontaneously in C57BL / 6 mice. hCCR8 transgenic C57BL / 6 mice were inoculated with the E0771 mouse breast cancer cell line, and then Hu149-11G1m was administered to tumor-bearing mice at a dose of 3mg / kg twice a week as a single agent or in combination with an anti-PD-1 antibody at a dose of 5mg / kg. Tumor growth was monitored throughout the study, and survival was recorded at the end of the study. An assessment of tumor infiltrating lymphocytes (TIL profile) was also performed to understand how Hu149-11G1m affects immune cells in the tumor microenvironment (TME). After isolating fresh tumors, CD4, CD8, and Treg were evaluated.
[0434] E0771 mouse breast cancer cells were cultured in RPMI medium supplemented with 10% FBS and 1x penicillin / streptomycin. After several in vitro passages, tumor cells were harvested using TrypLE Express reagent, counted, and diluted to 20E06 cells / mL in PBS. An equal volume of Matrigel was added to the cell solution to a final concentration of 10E06 cells / mL.
[0435] Transgenic hCCR8 mice were inoculated by injecting 50 μL of cell suspension into their right mammary fat pad. After 7 days of observation, the tumor volume of the mice was measured and 56 animals were divided into 4 treatment groups (14 animals in each group). The average tumor volume in each group was approximately 80 mm 3 Tumor-bearing mice were injected twice weekly with the indicated dose levels of Hu149-11G1m, anti-PD-1, or 10 mg / kg human IgG1. Tumor volume was assessed twice weekly using the formula TV = 0.5 x L x W x W until the tumor volume approached 1500 mm 3 , and then the mice were humanely euthanized.
[0436] 7 days after tumor implantation, a subgroup of mice (n=4 / treatment group) was selected to harvest tumor tissue and perform TIL analysis. Tumor tissue was homogenized and digested with a tumor dissociation kit (Miltenyi 130-096-730). 3 million cells in each sample were stained and analyzed by flow cytometry.
[0437] The remaining mice (n=10 / treatment group) continued to be monitored twice weekly for health checks and tumor volume measurements. All mice without excessive tumor burden (TV ≥ 1500 mm 3 ) were maintained for survival assessment. As described in detail below, better survival was achieved in the combined treatment group and significant depletion of Tregs was observed.
[0438] Results: Combination therapy with 3 mg / kg Hu149-11G1m and 5 mg / kg anti-PD-1 further reduced the mean tumor volume, and this antitumor effect persisted after cessation of drug treatment (see Fig.24 ). Table 34 illustrates the tumor volume of individual animals on day 22 after tumor inoculation. Hu149-11G1m as a single agent and in combination with anti-PD-1 antibody resulted in a significant reduction in tumor growth compared to the negative control (human IgG1 with matching Fc) (p<0.05 and p<0.001). In addition, later on day 26 after tumor inoculation (Table 35), the combination treatment group showed an anti-tumor effect that was significantly superior to that of the Hu149-11G1m and anti-PD-1 monotherapy groups (p<0.01 and p<0.05). Fig.25As shown, the combination treatment also showed a survival benefit. In addition, there was no substantial mean weight loss in any of the groups treated with Hu149-11G1m alone or in combination with anti-PD-1 antibodies. Together, these data suggest that CCR8 antibodies, such as Hu149-11G1m, can mediate anti-tumor activity in vivo and, in addition, can provide sensitivity to anti-PD-1 antibodies.
[0439] Table 34: Tumor volume and statistical data on day 22 after the start of treatment
[0440] treat Number of animals Mean Standard error of the mean One-way ANOVA Comparison 8 869.1 114.6 NA Hu149-11G1m 9 522.3 75 <![CDATA[0.04 a ]]> Anti-PD-1 10 446.9 94.3 <![CDATA[0.009 b ]]> Combination therapy 10 194.6 60.1 <![CDATA[<0.001 c ]]>
[0441] a , b and c Comparison of treatment group with control group; NA: Not applicable
[0442] Table 35: Tumor volume and statistical data on day 26 after the start of treatment
[0443] treat Number of animals Mean Standard error of the mean <![CDATA[T test a ]]> Hu149-11G1m 6 845.7 121 <![CDATA[0.006 a ]]> Anti-PD-1 7 545.4 145 <![CDATA[0.04 b ]]> Combination therapy 9 178.8 49 NA
[0444] a Hu149-11G1m was compared with the combination treatment group; b Comparison of anti-PD-1 and combination therapy
[0445] NA: Not applicable.
[0446] The current study also found that the administration of Hu149-11G1m and anti-PD-1 antibody induced a significant depletion of Tregs in tumors and led to an increase in the CD8+ T / Treg ratio, Fig.26 (p<0.05, four animals per treatment group were selected to harvest tumor tissue, collect immune cells and stain for flow cytometry analysis). There were no significant changes in other immune cell populations.
[0447] Example 29: Binding of FC variants of humanized anti-CCR8 antibodies to TALL-1 cells
[0448] TALL-1 is a human T-cell leukemia cell line that endogenously expresses CCR8 at levels comparable to those observed in tumor-infiltrating Treg cells and was further used to investigate the binding activity of the Fc variants of humanized anti-CCR8 antibodies. 4Cells were seeded in 96-well plates and washed once with FACS buffer (DPBS containing 1.5% FBS). Antibodies were prepared in 3-fold serial dilutions from 100nM to 0.00508nM in FACS buffer. Cells were incubated with 50μL of diluted antibodies at 4°C for 40 minutes. After primary antibody incubation, cells were washed twice with FACS buffer. Then, Alexa Flu647-labeled anti-human IgG Fc secondary antibodies (JacksonImmunoResearch, #109606170) were diluted 1:500 in FACS buffer and stained at 4°C for 40 minutes. After washing twice with FACS buffer, flow cytometry (BD FACS Celesta) was performed to measure the binding affinity of the antibodies.
[0449] As shown in Table 36, Hu149-11G1m, Hu149-11G1 (wild-type Fc variant), and TPP21360 (wild-type Fc variant) showed similar binding activity to TALL-1 cells, EC 50 The maximum MFI values of Hu149-11G1m, Hu149-11G1 (wild-type variant) and TPP21360 (wild-type variant, see WO2021152186) are also similar.
[0450] Table 36: Binding activity of Fc variants of humanized 149 antibody to TALL-1 cells
[0451] Antibody <![CDATA[EC 50 (nM)]]> Maximum MFI Hu149-11G1m 0.328 107 Hu149-11G1 0.315 111 TPP21360 0.461 102 HuIgG1-G1m isotype NA 5.96
[0452] “NA” means “Not Applicable”
[0453] Example 30: ADCC activity of anti-CCR8 antibodies
[0454] ADCC reporter bioassays were performed to compare the ADCC activity of anti-CCR8 antibodies against TALL-1 cells, and the levels of CCR8 expressed by TALL-1 cells were comparable to those observed in tumor-infiltrating Treg cells. In this case, anti-CCR8 antibodies, Hu149-11G1, Hu10A11-1, and TPP21360 all had wild-type IgG1-Fc, and isotype controls were used in this study. The method is as described above (see Example 22). As shown in Table 37, in this assay, Hu149-11G1 was significantly stronger than Hu10A11-1 and TPP21360. When 158V CD16a / NFAT-Jurkat and 158F CD16a / NFCTJurkat cells were used as alternative effector cells, the EC of Hu149-11G1 was significantly stronger than that of Hu10A11-1 and TPP21360. 50The EC values of Hu10A11-1 and TPP21360 were 0.0658 nM and 0.120 nM, respectively. 50 Value not applicable in this assay.
[0455] Table 37: ADCC activity of anti-CCR8 antibodies with CD16a / NFAT-Jurkat reporter cells against TALL-1 cells
[0456]
[0457] “NA” means “Not Applicable”
[0458] A human PBMC-based ADCC assay was further performed to compare the ADCC activity of the anti-CCR8 antibodies. Human PBMCs (AllCells) were cultured overnight in T75 flasks in RPMI 1640 medium containing 10% heat-inactivated FBS and 200 IU IL-2 (Development, catalog number: 202-IL). In a 96-well plate, 2×10 4 TALL-1 cells were co-cultured with pre-activated PBMCs (ratio 1:20), and the cells were incubated with RPMI 1640 containing 2% heat-inactivated FBS for 4 hours. At the end of the incubation, the lysis buffer was added to the assay plate and incubated for 30 minutes, and then the LDH working solution (DOJINDO, catalog number: CK12) was added to the assay plate and incubated for 25 minutes. After the stop solution was added to the assay plate, the absorbance value at 490nm was measured by a microplate reader. Nonlinear regression analysis was performed by Prism8 (GraphPad software), and EC was calculated. 50 Values (log(agonist) vs. response - variable slope (four parameters)). Specific cytotoxicity was calculated by the formula: Specific cytotoxicity % = (ER-ER0) / [(TMR-VCC)-(TSR-CMB)] × 100. ER indicates experimental release; ER0 indicates experimental release without antibody; TMR indicates maximum release from target cells; VCC indicates volume correction control; TSR indicates spontaneous release from target cells; CMB indicates control for medium background.
[0459] As shown in Table 38, Hu-149-11G1 (wild-type Fc variant) was 45.7 times more potent than TPP21360 (wild-type Fc variant) in the ADCC assay, with an EC 50 The maximum specific lysis rates were 13.8% and 10.2%, respectively. Compared with Hu149-11G1 (wild-type variant), Hu149-11G1m (ADCC enhanced variant) significantly improved the ADCC activity of TALL-1 cells. The EC of Hu149-110G1m was50 It is 0.000682nM, and the maximum specific lysis rate is 32.2%.
[0460] Table 38: ADCC activity of anti-CCR8 antibodies against TALL-1 cells with human PBMCs
[0461] Antibody <![CDATA[EC 50 (nM)]]> Maximum specific lysis rate (%) Hu149-11G1m 0.000682 32.2 Hu149-11G1 0.0121 13.8 TPP21360 0.553 10.2 HuIgG1-G1m isotype NA 0.57
[0462] “NA” means “Not Applicable”
[0463] Although the preferred embodiments of the present application have been shown and described herein, it is obvious to those skilled in the art that these embodiments are provided only as examples. Without departing from the present application, many modifications, changes and replacements will occur to those skilled in the art. It should be understood that various alternatives of the present application embodiments described herein can be adopted when practicing the present application. It is intended herein to limit the scope of the present application with the appended claims, and to encompass methods and structures within the scope of these claims and their equivalents.
Claims
1. An antigen binding unit comprising a light chain CDR and a heavy chain CDR, in The heavy chain CDR comprises HC-CDR1, HC-CDR2 and HC-CDR3, The light chain CDR comprises LC-CDR1, LC-CDR2 and LC-CDR3, The HC-CDR1, HC-CDR2 and HC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 13-15, 19-22, 71-73, 77, 78, 81, 83-85, 89, 91-93, 97, 98 and 112-118, and The LC-CDR1, LC-CDR2 and LC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 16-18, 23, 24, 25, 74-76, 79, 80, 82, 86-88, 90, 94-96 and 99-111. 2 . The antigen binding unit according to claim 1 , wherein the HC-CDR1, HC-CDR2 and HC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 13-15, 19-22, 89, 114 and 115.
3. The antigen binding unit according to claim 1, wherein the HC-CDR1, HC-CDR2 and HC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 83-85 and 116-118.
4. The antigen binding unit according to claim 1, wherein the HC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 13, 71, 83, 115 and 117, the HC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 14, 72, 77, 84, 89, 91, 92, 97, 114, 116 and 118, and the HC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 15, 19-22, 73, 78, 81, 85, 93, 98, 112 and 113.
5. The antigen binding unit according to claim 1, wherein the HC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 13 and 115, the HC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 14, 89 and 114, and the HC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 15 and 19-22.
6. The antigen binding unit according to claim 1, wherein the HC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 83 and 117, the HC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 84, 116 and 118, and the HC-CDR3 comprises the sequence of SEQ ID NO:
85.
7. The antigen binding unit according to any one of claims 1-6, wherein the LC-CDR1, LC-CDR2 and LC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 16-18, 23, 24, 25, 90 and 102-106.
8. The antigen binding unit according to any one of claims 1 to 6, wherein the LC-CDR1, LC-CDR2 and LC-CDR3 each comprise a sequence selected from the group consisting of SEQ ID NOs: 86-88.
9. The antigen binding unit according to any one of claims 1-6, wherein the LC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 16, 74, 79, 86, 90, 94, 99 and 102-109, the LC-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 17, 75, 80, 87, 95, 100, 110 and 111, and the LC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 18, 23-25, 76, 82, 88, 96 and 101.
10. The antigen binding unit according to any one of claims 1-6, wherein the LC-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 16, 90 and 102-106, the LC-CDR2 comprises a sequence of SEQ ID NO: 17, and the LC-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 18 and 23-25.
11. The antigen binding unit according to any one of claims 1 to 6, wherein the LC-CDR1 comprises the sequence of SEQ ID NO: 86, the LC-CDR2 comprises the sequence of SEQ ID NO: 87, and the LC-CDR3 comprises the sequence of SEQ ID NO:
88.
12. The antigen binding unit according to claim 1, wherein the HC-CDR1, HC-CDR2 and HC-CDR3 as a group respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 19; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 20; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 21; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 22; SEQ ID NO: 71, SEQ ID NO: 72 and SEQ ID NO: 73; SEQ ID NO: 71, SEQ ID NO: 77 and SEQ ID NO: 78; SEQ ID NO: 71, SEQ ID NO: 72 and SEQ ID NO: 81; SEQ ID NO: 83, SEQ ID NO: 84 and SEQ ID NO: 85; SEQ ID NO: 13, SEQ ID NO: 89 and SEQ ID NO:
90. SEQ ID NO:13, SEQ ID NO:91 and SEQ ID NO:15; SEQ ID NO:71, SEQ ID NO:92 and SEQ ID NO:93; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:98; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:112; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:113; SEQ ID NO:13, SEQ ID NO:114 and SEQ ID NO:15; SEQ ID NO:115, SEQ ID NO:114 and SEQ ID NO:15; SEQ ID NO:83, SEQ ID NO:116 and SEQ ID NO:85; SEQ ID NO:117, SEQ ID NO:116 and SEQ ID NO:85; and SEQ ID NO:83, SEQ ID NO:118 and SEQ ID NO:
85.
13. The antigen binding unit according to claim 1 or 12, wherein the LC-CDR1, LC-CDR2 and LC-CDR3 as a group respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 23; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 24; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 25; SEQ ID NO: 74, SEQ ID NO: 75 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 75 and SEQ ID NO: 82; SEQ ID NO: 86, SEQ ID NO: 87 and SEQ ID NO: 88; SEQ ID NO: 90, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 94, SEQ ID NO: 95 and SEQ ID NO: ID NO:96; SEQ ID NO:79, SEQ ID NO:75, and SEQ ID NO:76; SEQ ID NO:99, SEQ ID NO:100, and SEQ ID NO:101; SEQ ID NO:101, SEQ ID NO:17, and SEQ ID NO:18; SEQ ID NO:103, SEQ ID NO:17, and SEQ ID NO:18; SEQ ID NO:104, SEQ SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:105, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:106, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:107, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:108, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:109, SEQ ID NO:100, and SEQ ID NO:101; and SEQ ID NO:99, SEQ ID NO:111 and SEQ ID NO:
101.
14. The antigen binding unit according to claim 1, wherein the HC-CDR1, HC-CDR2, HC-CDR3, LC-CDR1, LC-CDR2 and LC-CDR3 as a group respectively comprise an amino acid sequence selected from the group consisting of: SEQ ID NOs: 13, 14, 15, 16, 17 and 18; SEQ ID NOs: 13, 14, 19, 16, 17 and 18; SEQ ID NOs: 13, 14, 20, 16, 17 and 18; SEQ ID NOs: 13, 14, 21, 16, 17 and 18; SEQ ID NOs: 13, 14, 22, 16, 17 and 18; SEQ ID NOs: 13, 14, 15, 16, 17 and 23; SEQ ID NOs: 13, 14, 15, 16, 17 and 24; SEQ ID NOs: 13, 14, 15, 16, 17 and 25; NO:13, 14, 19, 16, 17 and 23; SEQ ID NO:13, 14, 20, 16, 17 and 23; SEQ ID NO:13, 14, 21, 16, 17 and 23; SEQ ID NO:13, 14, 22, 16, 17 and 23; SEQ ID NO:13, 89, 15, 90, 17 and 18; SEQ ID NO:13, 89, 15, 102, 17 and 18; SEQ ID NO:13, 89, 15, 103, 17 and 18; SEQ ID NO:13, 89, 15, 104, 17 and 18; SEQ ID NO:13, 89, 15, 16, 17 and 18; SEQ ID NO:13, 89, 15, 105, 17 and 18; SEQ ID NO:13, 89, 15, 106, 17 and 18; ID NOs: 13, 114, 15, 16, 17 and 18; and SEQ ID NOs: 115, 114, 15, 16, 17 and 18.
15. The antigen binding unit according to claim 1, wherein the HC-CDR1, HC-CDR2, HC-CDR3, LC-CDR1, LC-CDR2 and LC-CDR3 as a group respectively comprise an amino acid sequence selected from the following groups: SEQ ID NO: 83, 84, 85, 86, 87 and 88; SEQ ID NO: 83, 116, 85, 86, 87 and 88; SEQ ID NO: 117, 116, 85, 86, 87 and 88; and SEQ ID NO: 83, 118, 85, 86, 87 and 88.
16. The antigen binding unit of claim 1, wherein the heavy chain CDR comprises a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70.
17. The antigen binding unit according to claim 1 or 16, wherein the light chain CDR comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60 and 62-65.
18. The antigen binding unit of claim 1, wherein the heavy chain CDR and the light chain CDR as a group respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 2; SEQ ID NOs: 3 and 2; SEQ ID NOs: 4 and 2; SEQ ID NOs: 5 and 2; SEQ ID NOs: 6 and 2; SEQ ID NOs: 7 and 2; SEQ ID NOs: 1 and 8; SEQ ID NOs: 1 and 9; SEQ ID NOs: 1 and 10; SEQ ID NOs: 3 and 8; SEQ ID NOs: 4 and 8; SEQ ID NOs: 5 and 8; SEQ ID NOs: 6 and 8; SEQ ID NOs: 11 and 8; SEQ ID NOs: 12 and 8; SEQ ID NOs: 34 and 35; SEQ ID NOs: 34 and 43; SEQ ID NOs: 34 and 44; SEQ ID NOs: 34 and 45; SEQ ID NOs: 34 and 46; SEQ ID NOs: 34 and 47; SEQ ID NOs: 34 and 48; SEQ ID NOs: 56 and 2; SEQ ID NOs: 57 and 2; SEQ ID NOs: 58 and 2; SEQ ID NOs: 59 and 60; SEQ ID NOs: 61 and 61; SEQ ID NOs: 62 and 63; SEQ ID NOs: 64 and 64; SEQ ID NOs: 65 and 66; SEQ ID NOs: 67 and 68; SEQ ID NOs: 69 and 70; SEQ ID NOs: 71 and 72; SEQ ID NOs: 73 and 74; SEQ ID NOs: 75 and 76; SEQ ID NOs: 77 and NO:58 and 2; SEQ ID NO:59 and 2; SEQ ID NO:56 and 60; SEQ ID NO:57 and 60; SEQ ID NO:58 and 60; and SEQ ID NO:59 and 60.
19. The antigen binding unit of claim 1, wherein the heavy chain CDR and the light chain CDR as a group respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 32 and 33; SEQ ID NOs: 61 and 62; SEQ ID NOs: 61 and 63; SEQ ID NOs: 61 and 64; SEQ ID NOs: 61 and 65; SEQ ID NOs: 66 and 62; SEQ ID NOs: 67 and 62; SEQ ID NOs: 68 and 62; SEQ ID NOs: 69 and 62; and SEQ ID NOs: 70 and 62.
20. The antigen binding unit according to any one of the preceding claims, wherein the antigen binding unit is a monoclonal antibody, a humanized antibody or a chimeric antibody.
21. The antigen binding unit according to any one of claims 1 to 19, wherein the antigen binding unit is scFv, Fab', single chain Fab (scFab'), Fd or F(ab')2.
22. The antigen binding unit according to any one of claims 1-20, comprising an IgG1 framework.
23. The antigen binding unit according to claim 22, comprising one or more mutations in the Fc region.
24. The antigen binding unit of claim 23, wherein the one or more mutations comprise S239D mutation, I332E mutation, L235V mutation, F243L mutation, R292P mutation, Y300L mutation, P396L mutation or a combination thereof.
25. The antigen binding unit according to claim 23 or 24, wherein the one or more mutations enhance antibody-dependent cellular cytotoxicity (ADCC).
26. The antigen binding unit according to any one of the preceding claims, wherein the antigen binding unit binds to human CC motif chemokine receptor 8 (CCR8), or cynomolgus monkey CCR8, or a combination thereof.
27. The antigen binding unit according to any one of the preceding claims, wherein the antigen binding unit blocks chemokine CC motif ligand 1 (CCL1).
28. A pharmaceutical composition comprising the antigen binding unit of any one of claims 1-27 and a pharmaceutically acceptable excipient.
29. An isolated nucleic acid encoding the antigen binding unit of any one of claims 1-27.
30. A vector comprising a nucleic acid sequence encoding the antigen binding unit of any one of claims 1-27.
31. A host cell expressing the antigen binding unit of any one of claims 1-27.
32. A host cell comprising a nucleic acid encoding the antigen binding unit of any one of claims 1-27.
33. A method for producing an antigen binding unit according to any one of claims 1 to 27, comprising: Cultivating the host cell of claim 31 or 32 under conditions suitable for expressing the antigen binding unit; as well as The antigen binding unit expressed by the host cell is isolated.
34. A method of treating cancer in a subject, comprising: Administering an effective amount of the antigen binding unit of any one of claims 1 to 27 or an effective amount of the pharmaceutical composition of claim 28 to a subject in need thereof; The administration is optionally repeated over a period of time.
35. The method of claim 34, wherein the antigen binding unit is administered at a dose of about 0.1 mg / kg to about 10 mg / kg.
36. The method of claim 34 or 35, wherein the subject is a human patient in need of anti-cancer treatment.
37. The method of any one of claims 34-36, wherein the cancer is colorectal cancer (CRC), breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), melanoma, renal cancer, bladder cancer, or sarcoma.
38. A method for eliminating an immune cell population, comprising: The immune cell population is contacted with the antigen binding unit of any one of claims 1 to 27.
39. The method of claim 38, wherein the immune cell is a regulatory T cell (Treg).
40. The method of claim 39, wherein the Tregs are contained in the tumor as a subpopulation of tumor infiltrating lymphocytes (TIL).
41. The method of any one of claims 39-40, wherein the Tregs are associated with colorectal cancer (CRC), breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), melanoma, hepatocellular carcinoma (HCC), renal cancer, bladder cancer, or pancreatic ductal adenocarcinoma (PDAC).
42. A method of treating cancer in a subject in need thereof, comprising: Targeting a subpopulation of tumor infiltrating lymphocytes (TILs) in the subject, comprising the steps of: administering the pharmaceutical composition of claim 28 to the subject; and repeating the administering step.
43. The method of claim 42, wherein the TIL subpopulation is regulatory T cells (Tregs).
44. The method of claim 42 or 43, wherein the antigen binding unit inhibits Treg migration, eliminates Tregs by antibody-dependent cellular cytotoxicity (ADCC), or both.
45. The method of any one of claims 42-44, wherein the antigen binding unit is administered at a dose of about 0.1 mg / kg to about 10 mg / kg.
46. The method of any one of claims 42-45, wherein the subject is a human patient in need of anti-cancer treatment.
47. The method of any one of claims 42-46, wherein the cancer is colorectal cancer (CRC), breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), melanoma, hepatocellular carcinoma (HCC), renal cancer, bladder cancer, or pancreatic ductal adenocarcinoma (PDAC).
48. The method of any one of claims 34-47, further comprising administering one or more therapeutic antibodies.
49. The method of claim 48, wherein the one or more therapeutic antibodies are one or more immune checkpoint inhibitors.
50. The method of claim 48, wherein the immune checkpoint inhibitor is an anti-PD-1, anti-PD-L1, or anti-CLTA-4 antibody.
